Evaluation of gastrointestinal transit time and novel oral acetaminophen product formulation by Ayres, James W.
AN ABSTRACT OF THE THESIS OF
Mohammad Hossain for the degree of Doctor of Philosophy in Pharmacy
presented on April 10, 1991.
Title: Evaluation Of Gastrointestinal Transit Time And Novel Oral
Acetaminophen Product Formulation.
Abstract approved:,Redacted for Privacy
James W. Ayres,h.D.
Gastrointestinal (GI) transit data were collected using pigs
as animal models.Density and size effects of non-disintegrating
dosage forms on GI transit were investigated.Total GI transit
times range from 2 to 33 days for 22 administrations of these non-
disintegrating dosage forms.Pigs are found to not be an
appropriate animal model for studying bioavailability or GI transit
of non-disintegrating, non-erodible oral release dosage forms.
Development of controlled release dosage forms where the
mechanism of drug release is diffusion through polymeric membrane
formed via film coating utilizing fluid-bed technology requires
optimization of several processing and formulation variables.The
influence of a processing variable (nozzle orifice opening) anda
few formulation variables (individual vs. combination plasticizer,
or a water-insoluble additive) on dissolution of a model drug
(acetaminophen) spray coated with Aquacoat® were studied.
Pharmacodynamic and pharmacokinetic information for a modeldrug (acetaminophen) and computer simulationwere used to develop a
dosage form with a 12 hour sustained release for oraladminis-
tration to children and adults for maximum analgesic and
antipyretic effect.Simulated plasma acetaminophen concentration-
time curves were similar to observed bioavailability study
profiles.In vitro and preliminary in vivo results froman adult
human volunteer indicate that sustained therapeuticsaliva
acetaminophen concentration is possible using the newlydeveloped
acetaminophen molded tablet dosage form.
The bioavailability of the new, oral controlled release
acetaminophen molded tablet relative toa commercially available
product (Extra-Strength Tylenol® caplet)was evaluated in 8
healthy, adult volunteers.Multiple doses of these two products
were administered in a two-way cross-over design.Bioavailability
of the new sustained release molded tablet is comparableto that of
the immediate release product.Polymer coated acetaminophen beads
were effective in maintaining saliva acetaminophen concentrations
of 5 gg/mL over a 12 hour dosing interval.Evaluation of Gastrointestinal Transit Time
and
Novel Oral Acetaminophen Product Formulation
by
Mohammad Hossain
A THESIS
submitted to
Oregon State University
in partial fulfillment of
the requirements for the
degree of
Doctor of Philosophy
Completed April 10, 1991
Commencement June, 1991APPROVED:
Redacted for Privacy
ProfeCrof Pharmacy inChlaeof Major
Redacted for Privacy
Dean of College of Pharmacy
Redacted for Privacy
Dean of Graduate /Shool
Date thesis is presented April 10, 1991.
Presented byMohammad Hossain.ACKNOWLEDGEMENTS
I would like to dedicate this thesis to my parents for their
love, encouragement and support.I would like to thank Dr. James
W. Ayres for his continued support, assistance and valuable advice
throughout my graduate studies.I would like to thank my fellow
graduate students for their help and friendship, and I am greatly
appreciative of those who volunteered for the bioavailability
study.I also greatly appreciate the valuable assistance of
Barbara J. Watrous D.V.M. and Richard Kay of the College of
Veterinary Medicine, OSU for their excellent technical assistance
and interpretation of all radiographic work.I would also like to
express my sincere appreciation to Dr.I. Ghebre-Sellassie of
Warner-Lambert/Parke-Davis Pharmaceutical Research and Robert E.
Parkington of Aeromatic Inc. for providing the methodology for
producing the drug-loaded beads and nozzles respectively, for the
spray coating experiments.I am also grateful to FMC Corporation
and Hercules Inc. for supplying samples of Aquacoat® and Klucel,
respectively.Last, but not least, my greatest thanks goes to my
wife, Rumana.Her understanding, patience and love make this truly
meaningful.TABLE OF CONTENTS
INTRODUCTION 1
CHAPTER I: EVALUATION OF GASTROINTESTINAL TRANSIT TIME OF 2
NON-DISINTEGRATING, NON-ERODIBLE ORAL DOSAGE
FORMS IN PIGS
ABSTRACT 2a
INTRODUCTION 3
MATERIALS AND METHODS 7
RESULTS AND DISCUSSION 17
CONCLUSIONS 28
REFERENCES 30
CHAPTER II:ANALYSIS OF VARIABLES INFLUENCING COAT INTEGRITY 34
FOR CONTROLLING DRUG RELEASE
ABSTRACT 35
INTRODUCTION 36
MATERIALS AND METHODS 39
RESULTS AND DISCUSSION 48
CONCLUSIONS 69
REFERENCES 70
CHAPTER III: PHARMACOKINETICS AND PHARMACODYNAMICS IN 73
ACETAMINOPHEN CONTROLLED RELEASE DOSAGE
FORM DESIGN
ABSTRACT 74
INTRODUCTION 75
MATERIALS AND METHODS 77
RESULTS AND DISCUSSION 92
CONCLUSIONS 128REFERENCES 130
CHAPTER IV: MULTIPLE DOSE PHARMACOKINETICS AND RELATIVE 132
BIOAVAILABILITY OF A NOVEL SUSTAINED RELEASE
ACETAMINOPHEN MOLDED TABLET
ABSTRACT 133
INTRODUCTION 134
MATERIALS AND METHODS 137
RESULTS AND DISCUSSION 148
CONCLUSIONS 165
REFERENCES 167
BIBLIOGRAPHY 171
APPENDICES 182LIST OF FIGURES
Figure Page
I.1 Dosage forms used in GI transit study. 12
1.2 X-ray photograph of dosage forms used in the study. 13
Small stainless steel rods inserted in dosage forms
help radiographic visualization and identification.
Left to right (density)Teflon 2.30 gm/mL, PVC 1.45
gm/mL, Nylon 1.25 gm/mL.Top to bottom (size)- Large
20 X 10 mm, Medium 10 X 10 mm, Small 5 X 10 mm.
1.3 GI transit subject in minimum stress Panepinto sling. 16
1.4 Radiograph of small size caplets in swine.The low 19
density caplet is in the stomach and the high density
caplet in the colon (dorso-ventral view).
I.5aRadiograph of large size caplet in swine.The medium 20
density caplet is in the small intestine (dorso-
ventral view).
I.5bRadiograph of large size caplet in swine.The medium 21
density caplet is in the small intestine (lateral
view).
I.6aRadiograph of large size caplet in swine.The medium 22
density caplet is in the vicinity of the spiral colon
(dorso-ventral view).
I.6bRadiograph of large size caplet in swine.The medium 23
density caplet is in the vicinity of the spiral colon
(lateral view).
1.7 Average gastric residence time in pigs for high-,
medium-, and low-density non-erodible, rigid oral
dosage forms having large, medium and small sizes.
II.laDifferent methods of sample preparation for SEM.
Method A = samples fractured in liquid nitrogen.
Magnification X500.
II.lbDifferent methods of sample preparation for SEM.
Method B = samples sliced with a sharp surgical
blade.Magnification X500.
II.lcDifferent methods of sample preparation for SEM.
Method C = samples sliced with a sharp surgical
blade, dissolved in 100 mL distilled water for 6 hr
at 37°C, then filtered using a 0.45 Am membrane
25
49
50
51filter, and finally air-dried in the oven for 4 hr.
Magnification X250.
11.2 Effect of temperature and type of coating formulation 52
(see Table II.1) on coat thickness.(0) = 45°C and
() = 75°C.
II.3aEffect of temperature (45°C) on coat morphology. 53
Magnification X1000.
II.3bEffect of temperature (75°C) on coat morphology. 54
Magnification X1000.
11.4Effect of base plate on coat thickness. (0) = 45°C 56
and () = 75°C.
11.5Typical SEM photograph of whole coated bead. 58
Magnification X50.
11.6Typical SEM photograph of cross-section of coated bead 59
showing three distinct layers - inner sugar core,
middle drug layer, and outer coating layer.
Magnification X100.
II.7aEffect of nozzle size on coat morphology.2.5 mm 60
nozzle.Magnification X1000.[Formulation 4 (See
Table II.1), Temperature 75°C)].
II.7bEffect of nozzle size on coat morphology.1.2 mm 61
nozzle.Magnification X1000.[Formulation 4 (See
Table II.1), Temperature 75°C)].
II.7cEffect of nozzle size on coat morphology.0.8 mm 62
nozzle.Magnification X1000.[Formulation 4 (See
Table II.1), Temperature 75°C)].
II.7dEffect of nozzle size on coat morphology.0.5 mm 63
nozzle.Magnification X1000.[Formulation 4 (See
Table II.1), Temperature 75°C)].
11.8Effect of nozzle orifice on coat thickness and drug 64
release.( °) = coat thickness and () = time to 50%
dissolution.Standard deviation error bars are shown
except in those cases where they are smaller than the
symbol.
11.9Effect of plasticizer on coat thickness and on drug 66
release using a nozzle orifice of 1.2 mm.( °) = coat
thickness and () = time to 50% dissolution.Standard
deviation error bars are shown except in those cases
where they are smaller than the symbol.II.10Effect of talc on drug release using a nozzle orifice 67
of 1.2 mm.(o) = coat thickness and (.) = time to
50% dissolution.
III.1Hand molding apparatus used for making molded 86
tablets.
111.2Antipyretic effect of acetaminophen in febrile 93
children (dose = 10 mg/kg).(41) plasma concentration
(ref. 12), (0) mean temperature decrement (ref. 12),
(v) and (A) mean temperature decrement (ref. 15 and
ref. 16 respectively).
111.3Analgesic effect of acetaminophen in febrile 94
children (dose 10 mg/kg).(I) plasma concentration
(ref. 12),(0) pain intensity difference and (o)
pain relief score (both ref. 14).
111.4Analgesic-antipyretic effect of acetaminophen in 95
febrile children.Effect-concentration data points
are connected in order of decreasing time 1 h after
maximum plasma concentration. (0) and (o) pain
intensity difference and pain relief score
respectively (ref. 14), (0) mean temperature
decrement (ref. 12), (A) mean temperature decrement
(ref. 16), (v) mean temperature decrement (ref. 15),
and () mean temperature decrement (ref. 17).
111.5Counterclockwise hysteresis loop between plasma 97
concentration and antipyretic effect plotted in
order of increasing time. (0) mean temperature
decrement (ref. 12), (A) mean temperature decrement
(ref. 16), and (v) mean temperature decrement (ref.
15).
III.6aMaxsim® computer simulation of plasma acetaminophen 98
concentration in 2-3 year old children.Immediate
release portion of 80 mg and sustained release
portion of 300 mg (total dose = 380 mg) given every
12 hours.
III.6bMaxsim® computer simulation of plasma acetaminophen 99
concentration in 2-3 year old children.Usual
immediate release dose of 160 mg given every 6
hours.
III.7aMaxsim® computer simulation of plasma acetaminophen 101
concentration in adults.Immediate release portion
of 500 mg and 3% Aquacoat sustained release portion
of 1500 mg (total dose = 2000 mg) given every 12
hours.III.7bMaxsim® computer simulation of plasma acetaminophen 102
concentration in adults.Immediate release portion
of 400 mg APAP and 3% or 2.5% Aquacoat sustained
release portion of 2000 mg APAP (total dose = 2400
mg) given every 12 hours.
III.7cMaxsim® computer simulation of plasma acetaminophen 103
concentration in adults.Usual immediate release
dose of 1000 mg given every 6 hours.
111.8 Dissolution profile of acetaminophen beads coated 104
with Aquacoat ®.Standard deviation error bars are
shown except in those case where they are smaller
than the symbol.
111.9 Dissolution profile of acetaminophen beads coated 105
with Aquacoat ®.
III.10Simple linear regression fitting of dissolution 106
data.
III.11 Effect of coating amount on acetaminophen release 108
rate.
111.12Effect of actual coat thickness on time to 50% 111
dissolution (d50%) of acetaminophen.
III.13aDissolution profile of two different batches of 3% 113
Aquacoat® (AQ) pellets.
III.13bSimple linear regression of dissolution data of two 114
different batches of 3% Aquacoat® (3% AQ-I and 3%
AQ-II).
III.14aDissolution profile of two different batches of 115
2.5% Aquacoat® (AQ) pellets and 3% Aquacoat® (AQ).
III.14bSimple linear regression of dissolution data of two 116
different batches of 2.5% Aquacoat® (AQ) and 3%
Aquacoat® (AQ).
III.15aScanning electron micrograph of uncoated APAP 117
loaded bead produced with a 1.2 mm nozzle opening.
Magnification X50.
III.15bScanning electron micrograph of uncoated APAP 118
loaded bead produced with a 0.8 mm nozzle opening.
Magnification X50.
III.16aDissolution profile of molded tablet and unmolded 120
pellets using formulation 3.III.16bSimple linear regression of dissolution data of
molded tablet and unmolded pellets using
formulation 3.
121
III.17aDissolution profile of molded tablets aged one day, 122
one week, and one month produced using formulation
3.
III.17bSimple linear regression of dissolution data of 123
molded tablets aged one day, one week, and one
month produced using formulation 3.
111.18Saliva acetaminophen (APAP) concentration-time 124
profiles (12-24 hour data) for one subject
receiving two different molded tablet formulations
containing an immediate (Imm) and a sustained
release Aquacoat® (AQ) portion.
111.19Minimum saliva acetaminophen (APAP) concentration 127
(Cmin; 0, 12, and 24 hour data) following adminis-
tration of two molded tablets of formulation 1
(2000 mg dose) and formulation 2 (2400 mg dose)
containing an immediate (Imm) and a sustained
release Aquacoat® (AQ) portion.
IV.1 Typical chromatogram for acetaminophen and 2- 144
acetamidophenol.
IV.2 Plot of peak area ratios of acetaminophen 145
(APAP):internal standard (I.S.) versus known
acetaminophen concentration.
IV.3 Mean saliva acetaminophen concentration-time 151
profiles for all subjects.Extra-Strength Tylenol®
caplet (1000 mg dose, 12-18 hour data) and molded
tablet (2400 mg dose, 24-36 hour data).
IV.4 Variability of average concentration time profiles 152
(12-18 hour) for subjects receiving Extra-Strength
Tylenol® caplets (1000 mg dose).Standard deviation
error bars are shown except in those cases when they
are smaller than the symbol.
IV.5 Variability of average concentration time profiles 153
(24-36 hour) for subjects receiving molded tablet
(2400 mg dose).Standard deviation error bars are
shown except in those cases when they are smaller
than the symbol.
IV.6 Variability of average minimum saliva acetaminophen 154
concentration (Cmin) for Extra-Strength Tylenol®caplet (1000 mg dose; 0, 6, 12, and 18 hour data)
and molded tablet (2400 mg dose; 0,12, 24, and 36
hour data).Standard deviation error bars are shown.LIST OF TABLES
Table Page
1.1Composition of commercial pig feed. 8
1.2Composition of non-disintegrating magnesium 9
hydroxide caplet.
1.3Composition of enteric coating solution. 11
1.4Transit time in pigs for high, medium, and low density 18
non-erodible, rigid oral dosage forms having large,
medium, and small sizes.
II.1Aquacoat coating formulations applied to 25-30 mesh 40
non-pareil sugar beads - variable temperature-
plasticizer combinations.
11.2Typical processing conditions used for the temperature- 41
plasticizer study for application of Aquacoat to non-
pareil sugar pellets.
11.3Typical processing conditions for application of 44
Aquacoat to APAP beads.
III.1One compartment open model pharmacokinetics of APAP in 78
febrile children.
111.2Typical processing conditions for Aquacoat® coated 82
APAP pellets (STREA-1, Aeromatic).
111.3Composition of molded tablet for acetaminophen pellets 83
(Formulation 1).
111.4Composition of molded tablet for acetaminophen pellets 84
(Formulation 2).
111.5Composition of molded tablet for acetaminophen pellets 85
(Formulation 3).
111.6Effect of coating level on APAP release rate. 107
111.7Effect of coating on coat thickness and drug release. 110
111.8Pharmacokinetic parameters following oral adminis- 125
tration of acetaminophen molded tablets calculated
by non-compartmental methods.
IV.1Vital statistics of subjects. 138IV.2Composition of molded tablet for acetaminophen pellets. 139
IV.3Pharmacokinetic parameters (steady state 12-18 hour) 149
for one compartment open model following multiple oral
administration of 2 X 500 mg Extra-Strength Tylenol®
caplets.
IV.4One compartment open model pharmacokinetic parameters 156
determined from average concentration-time profile (12-
18 hour) for Extra-Strength Tylenol® caplet (1000 mg
dose).
IV.5Non-compartmental pharmacokinetic parameters for 158
acetaminophen following multiple oral administration of
2 X 500 mg Extra-Strength Tylenol® Caplets (1000 mg
dose).
IV.6Non-compartmental pharmacokinetic parameters for 159
acetaminophen following multiple oral administration of
2 X 1200 mg Molded Tablets (2400 mg dose).
IV.7Summary statistics for average pharmacokinetic 161
parameters following oral administration of
acetaminophen products calculated by non-compartmental
methods.
IV.8Non-compartmental pharmacokinetic parameters for
acetaminophen products determined from average saliva
acetaminophen concentration-time profile.
164LIST OF APPENDIX FIGURES
Figure Page
A.1Observed saliva acetaminophen concentration-time 183
profiles for subject 1.Extra-Strength Tylenol® caplet
(1000 mg dose, 12-18 hour data) and molded tablet (2400
mg dose, 24-36 hour data).
A.2Observed saliva acetaminophen concentration-time 184
profiles for subject 2.Extra-Strength Tylenol® caplet
(1000 mg dose, 12-18 hour data) and molded tablet (2400
mg dose, 24-36 hour data).
A.3Observed saliva acetaminophen concentration-time 185
profiles for subject 3.Extra-Strength Tylenol® caplet
(1000 mg dose, 12-18 hour data) and molded tablet (2400
mg dose, 24-36 hour data).
A.4Observed saliva acetaminophen concentration-time 186
profiles for subject 4.Extra-Strength Tylenol® caplet
(1000 mg dose, 12-18 hour data) and molded tablet (2400
mg dose, 24-36 hour data).
A.5Observed saliva acetaminophen concentration-time 187
profiles for subject 5.Extra-Strength Tylenol® caplet
(1000 mg dose, 12-18 hour data) and molded tablet (2400
mg dose, 24-36 hour data).
A.6Observed saliva acetaminophen concentration-time 188
profiles for subject 6.Extra-Strength Tylenol® caplet
(1000 mg dose, 12-18 hour data) and molded tablet (2400
mg dose, 24-36 hour data).
A.7Observed saliva acetaminophen concentration-time 189
profiles for subject 7.Extra-Strength Tylenol® caplet
(1000 mg dose, 12-18 hour data) and molded tablet (2400
mg dose, 24-36 hour data).
A.8Observed saliva acetaminophen concentration-time 190
profiles for subject 8.Extra-Strength Tylenol® caplet
(1000 mg dose, 12-18 hour data) and molded tablet (2400
mg dose, 24-36 hour data).
B.1Minimum saliva acetaminophen concentration (C in) for 192
subject 1.Extra-Strength Tylenol® caplet (1000 mg
dose; 0, 6, 12, and 18 hour data) and molded tablet
(2400 mg dose; 0, 12, 24, and 36 hour data).
B.2Minimum saliva acetaminophen concentration (C in) for 193
subject 2.Extra-Strength Tylenol® caplet (1000 mgdose; 0, 6, 12, and 18 hour data) and molded tablet
(2400 mg dose; 0, 12, 24, and 36 hour data).
B.3Minimum saliva acetaminophen concentration (C in) for 194
subject 3.Extra-Strength Tylenol® caplet (1000 mg
dose; 0, 6, 12, and 18 hour data) and molded tablet
(2400 mg dose; 0, 12, 24, and 36 hour data).
B.4Minimum saliva acetaminophen concentration (C in) for 195
subject 4.Extra-Strength Tylenol® caplet (1000 mg
dose; 0, 6, 12, and 18 hour data) and molded tablet
(2400 mg dose; 0, 12, 24, and 36 hour data).
B.5Minimum saliva acetaminophen concentration (C in) for 196
subject 5.Extra-Strength Tylenol® caplet (1000 mg
dose; 0, 6, 12, and 18 hour data) and molded tablet
(2400 mg dose; 0, 12, 24, and 36 hour data).
B.6Minimum saliva acetaminophen concentration (C in) for 197
subject 6.Extra-Strength Tylenol® caplet (1000 mg
dose; 0, 6, 12, and 18 hour data) and molded tablet
(2400 mg dose; 0, 12, 24, and 36 hour data).
B.7Minimum saliva acetaminophen concentration (Cir) for 198
subject 7.Extra-Strength Tylenol® caplet (1000 mg
dose; 0, 6, 12, and 18 hour data) and molded tablet
(2400 mg dose; 0, 12, 24, and 36 hour data).
B.8Minimum saliva acetaminophen concentration (C min) for 199
subject 8.Extra-Strength Tylenol® caplet (1000 mg
dose; 0, 6, 12, and 18 hour data) and molded tablet
(2400 mg dose; 0, 12, 24, and 36 hour data).LIST OF APPENDIX TABLES
Table Page
C.1Saliva acetaminophen concentrations (gg/mL) following 201
oral administration of two 500 mg Extra-Strength
Tylenol® caplets (1000 mg dose) once every 6 hours
for a total of 3 doses.
C.2Saliva acetaminophen concentrations (gg/mL) following 202
oral administration of two 1200 mg molded tablets
(2400 mg dose) once every 12 hours for a total of 3
doses.EVALUATION OF GASTROINTESTINAL TRANSIT TIME
AND
NOVEL ORAL ACETAMINOPHEN PRODUCT FORMULATION
INTRODUCTION
Development of oral controlled-release drug delivery systems
is limited by a number of physiological and pharmaceutical factors
including gastrointestinal (GI) transit time, formulation
variables, and the drug delivery device itself.Chapter I of this
thesis deals with evaluation of GI transit time of non-
disintegrating, non-erodible oral dosage forms in pigs as animal
models.Chapter II deals with optimization of several processing
and formulation variables in designing controlled-release dosage
forms where the mechanism of drug release is diffusion through
polymeric membrane formed via film coating.Chapter III
concentrates on tailored dosage form design and optimization of
therapy utilizing computer simulations based on population average
pharmacodynamics and pharmacokinetics.Coated acetaminophen beads
with the desired release rate were then developed using fluid-bed
coating technology.Beads were later formulated into a new
sustained release acetaminophen molded tablet dosage form.Chapter
IV deals with evaluation of the experimental, easily swallowable,
oral sustained release acetaminophen molded tablet in healthy,
adult humans.2
CHAPTER I
EVALUATION OF GASTROINTESTINAL TRANSIT TIME OF NON-DISINTEGRATING,
NON-ERODIBLE ORAL DOSAGE FORMS IN PIGSABSTRACT 2a
Gastrointestinal (GI) transit data necessary as "base-line"
or "control" information were collected using pigs as animal models
preliminary to bioavailability studies of new sustained action
formulations.Density and size effects of non-disintegrating
dosage forms on GI transit were investigated.Initially, enteric
coated non-disintegrating magnesium hydroxide caplets (density 1.5
gm/mL, size 19.6 mm X 9.5 mm and weight 1.2 gm) were utilized in 7
pigs.Prolonged gastric residence (>5 days) occurred in every case
for this dosage form.Therefore, non-disintegrating caplets of
three densities (1.25, 1.45 and 2.3 gm/mL) and three different
sizes (large = 20 mm X 10 mm, medium = 10 mm X 10 mm and small = 5
mm X 10 mm) were studied in 2 more pigs.Roentgenography was used
to visualize passage of caplets through the GI tract.Heidelberg
pH capsules (size 8 mm X 20 mm with density 1.61 gm/mL) were also
used in this study.Total GI transit times range from 2 to 33 days
for 22 administrations of these non-disintegrating dosage forms.
Pigs are found to not be an appropriate model for evaluating
bioavailability of non-disintegrating controlled release dosage
forms because total G.I. transit time (especially gastric transit)
is much too long.3
INTRODUCTION
A significant limitation on development of oral controlled-
release drug delivery systems is gastrointestinal (GI) transit.In
humans, GI transit from mouth to colon has been estimated to be 8-
10 hr with transit being approximately 2-4 hr in the small
intestine (1).Relatively large tablets may empty rapidly (10-60
min) in undisintegrated form from a fasting stomach in people (2).
A non-disintegrating device designed to deliver a drug dose over 24
hr may have emptied from the stomach, traversed the small
intestine, and entered the colon in less than half that time (3).
This could result in reduced systemic drug concentrations and a
significant fraction of the dose being unabsorbed.
Hoelzel (1924), in his classic study of GI transit, showed
that passage of various substances through the digestive tract was
more or less proportional to their specific gravity with heavier
materials passing slower than light materials (4).Bechgaard and
Ladefoged (1978) suggested the use of density as a means of
modifying GI transit (5).However, in more recent studies such
differences in transit have not been confirmed.Davis et al(1986)
concluded that gastric emptying of non-disintegrating single unit
oral dosage forms will depend upon two major factors the presence
of food in the stomach and the size of the dosage form, not density
(6).Gastric emptying of solutions of drugs and small pellets
(less than 2 mm in size) occur quite rapidly from the fed stomach4
in humans while larger single unit systems are generally retained
until the stomach is empty of food and then expelled during phase
III contractions as described below (7).Gastric emptying patterns
in dogs in the fed state for particles having a size of less than 2
mm has also been shown to occur quite rapidly (8-11).It has also
been suggested that even a smaller particle size (less than 0.3 mm)
would be required for the particle to be emptied from the stomach
in the presence of food (12).Another report shows that both size
and shape influence movement of non-disintegrating dosage forms
from the stomach into the intestine in dogs (13).In contrast to
these reports, some larger non-disintegrating tablets (3-7 mm in
diameter) have been shown to empty from the stomach of man during
the digestive phase (14).
The transit behavior of indigestible solids can be generally
interpreted by reference to known physiological properties of the
GI tract, in particular the interdigestive myoelectric complex
(IMC).IMC is also known as the migrating myoelectric complex
(MMC) (15-25) and has been well-documented in dogs, pigs and
humans.This distinct cycle of contractile activity during the
fasting state begins in the proximal stomach and migrates aborally
through the small bowel.Gastric emptying of indigestible solids
occurs in conjunction with late phase II and the onset of phase III
MMC with a periodicity of about 2 hr in humans and in dogs (26-28).
The MMC in pigs recurr at intervals of 75-80 min (about 18/day) in
the fasting state, and the MMC cycle is similar when the animals5
are fed frequent but small meals (18).However, when pigs were fed
one large meal/day, or the food supplied as two meals/day, the
postprandial contractile activity lasted about 6 hr (about 13
MMC/day) and about 3 hr (about 16 MMC/day), respectively.The
propagation velocities of MMC's in the proximal bowel of three
species, pig, dog, and human, have been reported to be 20.6 ± 2.4
cm/min, 3.5-11.7 cm/min, and 6.44 ± 0.74 cm/min respectively
(27,29,30).
Pigs have been widely used to study the rate of passage of
food through the alimentary tract (31-34) because their digestive
tract appears physiologically and anatomically more similar to that
of humans than the tract of most other nonprimate animals.The
size of each section of the GI tract of the pig is comparable
anatomically to that of the human, and total body weight ranges are
similar (35).Increased application of swine in biomedical
research has resulted largely from an awareness that man and swine
have many biologic similarities, and therefore experimental data
obtained with swine may be extrapolated to man (36).Food is
normally emptied quickly from the stomach of pigs.Auffrey et al.
(1967) found that about 30-40% of ingesta passes into the duodenum
within 15 min in adult (about 50-70 kg) pigs (37).Dyed feed has
been found to be emptied from the stomach in 2.5-5.0 hr, and feed
passes through the stomach and small intestine much more rapidly
than through the large intestine (38).Experiments performed in
non-fasting pigs with indigestible polyetylene tubing having an6
outside diameter of 2 mm and 2 mm, 10 mm, or 20 mm long showed that
the 20 mm particles were retained for significantly longer periods
of time in the stomach (39,40).
GI transit of non-disintegrating sustained release products
in pigs might be expected to be similar to GI transit in humans.
If this is true, then pigs would be a good model for
bioavailability studies involving non-disintegrating controlled
release products.Specific objectives of this "base-line" study
were to :
1. Evaluate GI transit time of non-disintegrating prolonged action
dosage forms in pigs as animal models.
2. Examine the effect of density and size of non-disintegrating
dosage forms on GI transit in pigs.
3. Confirm the adequacy of the model and determine whether it
provides experimental results which can be extrapolated to
humans.7
MATERIALS AND METHODS
SUBJECTS
Nine young adult female White Yorkshire pigs (6-8 months old)
weighing approximately 45 kg were used.They were maintained on a
commercially available Murphy Feed (Hog Ration 14) diet (Table
I.1).The quantity fed was based on body weight (approx. 6.5
gm/kg/meal).The meal was fed twice a day at 7:30-8:00 am and
4:30-5:00 pm, moistened with water.
HOUSING
Pigs were housed and cared for by personnel at the Veterinary
Teaching Hospital at the College of Veterinary Medicine.Animals
were housed in small adjacent individual pens which have tubular
metal divisions and rubberized wire mesh overlying concrete floors
with a slope to facilitate regular washing and drainage of urine.
The animal pens (2.32 m2) allow reasonable space for free movement
and normal activity of the pig to allow normal gastrointestinal
motility.The housing area was kept lit during the daytime and
dark at night.
DOSAGE FORMS
Non-disintegrating magnesium hydroxide caplets (density 1.5
gm/mL, size 19.6 mm X 9.5 mm and weight 1.2 gm) containing 15%
bismuth as radiodense tracer (Table 1.2) were made on a Carver8
Table I.1Composition of commercial pig feed
Ingredient Type Percent
Protein (min.)
Fat (min.)
Fiber (max.)
Moisture (max.)
Added minerals (max.)
14.0
3.5
7.0
12.0
2.09
Table 1.2Composition of non-disintegrating magnesium hydroxide
caplet
Ingredients Amount (mg)
Bismuth' granules 100.0
Carbopol 934b 44.0
Magnesium stearatec 16.5
Magnesium hydroxided 1039.5
' Bismuth powder, 99.9999%, GOLD LABEL, Aldrich Chem. Co.,
Milwaukee, Wis.
bCarbopol 934, B.F. Goodrich Chemical Company, Division of the
B.F. Goodrich Co., Cleveland, OH.
Magnesium stearate (purified) Fischer Scientific Co.
dMagnesium hydroxide, Mallinckrodt, Inc., St. Louis, MO 63147.10
Press compressed to 4000 lbs.Caplets were then coated with
enteric coating solution (Table 1.3) by hand dipping.Heidelberg
pH capsules (size 8 mm X 20 mm with density 1.61 gm/mL) were also
utilized.
Additional dosage forms consisted of caplet "blanks" of non-
adhesive, non-wetting polymers, produced on a lathe from polymer
block (Figure I.1).Plastic caplets were drilled and small
stainless steel rods inserted to help radiographic visualization
and identification (Figure 1.2).Materials for caplet "blanks"
were :(i) Low densityNylon (density = 1.25 gm/mL), (ii) Medium
density - Polyvinylchloride (density = 1.45 gm/mL), and (iii) High
densityTeflon (density = 2.30 gm/mL).Non-disintegrating
caplets of the above three densities were produced in caplet shape
in the following three different sizes :(i) Large 20 mm (long)
by 10 mm (diameter), (ii) Medium10 mm (long) by 10 mm
(diameter), and (iii) Small 5 mm (long) by 10 mm (diameter).
DOSING
Each pig received all dosage forms by intubation on an empty
stomach (after about 12 hr of fasting), and were fasted about 8 hr
post dosing.All radiographs taken immediately prior to dosing
showed the stomach to be empty.
After dosing, each pig was administered 15-20 mL water with
an oral syringe.Otherwise, animals received their routine meals
and free access to water.Food in the stomach was readily visible11
Table 1.3Composition of enteric coating solution
Ingredients Amount
Hydroxypropyl methylcellulose phthalatea 7.00 gm
Dibutyl phthalateb 0.75 gm
Methylene chloride` 12.50 mL
Methanold 40.00 mL
a,bMallinckrodt, Inc., St. Louis, MO 63147.
bib J.T. Baker Chemical Co., Phillipsburg, NJ.12
LARGE
MEDIUM
SMALL
2.30
4.ft
[11111111101"
DENSITY
1.45 1.25
law
From leftMotrin SR containing bismuth,
Commercial Motrin, Heidelberg and Teflon caplets
Figure I.1Dosage forms used in GI transit study.Figure 1.2X-ray photograph of dosage forms used in the study.Small stainless steel rods
inserted in dosage forms help radiographic visualization and identification.
Left to right (density)Teflon 2.30 gm/mL, PVC 1.45 gm/mL, Nylon 1.25 gm/mL.
Top to bottom (size) Large 20 X 10 mm, Medium 10 X 10 mm, Small 5 X 10 mm. .--,
(,,)14
in radiographs taken following meals on subsequent days.Non-
disintegrating magnesium hydroxide caplets were administered to
each of seven pigs.In addition, the 9 polymer caplets were each
administered to two pigs for a total of 20 more administrations.
Treatments with different size and density caplets were
administered sequentially to each animal, each treatment (dosage
form) given after the previous dosage form had left the stomach and
been in the small intestine for at least 24 hr.
ANALYTICAL METHOD
Roentgenography was used to follow passage of non-
disintegrating caplets in the GI tract.Radiographs for pigs were
exposed at 0 min (just before dosing to ensure an empty stomach), 5
min (just after dosing to assure that the device was in the
stomach), and then every 24 hr since data from a pilot study
revealed gastric transit time required days.This sampling scheme
does not allow determination of gastric or intestinal exit times to
the hour (or even to half-day), but only provides monitoringon a
daily basis.This reduced radiation exposure for the pigs was
considered adequate since gastric residence time was usually
several days.Thus, transit times are slightly longer than
indicated, e.g., 5 days is more than 5 days but less than 6 days.
For each animal, radiographic examinations were performed
from two angles, a lateral view with a Fischer 41261G 300 mA Mobile
X-ray machine and a dorso-ventral view with a GE DXR 1050 X-ray15
machine.Dupont Cronex 4 film with Dupont Quanta III screens were
exposed at a distance of about 90 cm.Exposure settings were :
lateral view 1/10 sec at 300 mA and 80 KVP, and dorso-ventral view
1/10 sec at 700 mA and 80 KVP.Standard animal posture and
position were maintained during imaging using a minimum stress
Panepinto sling (Figure 1.3) [Department of Physiology and
Biophysics, College of Veterinary Medicine and Biomedical Sciences,
Colorado State University, Fort Collins, CO 80523].Each pig was
previously trained to stand quietly (supported by the sling), to
accept oral administration of water, and familiarized with the oral
dosing gun.Figure 1.3GI transit subject in minimum stress Panepintosling.17
RESULTS AND DISCUSSION
Orally administered non-disintegrating magnesium hydroxide
caplets remained in the stomach for at least 5 days!This
phenomenon was observed in 7 different pigs.After 5 days the
caplets started to dissolve in the gastric fluid even though they
were enteric-coated.Prolonged exposure to gastric acid and
enzymes resulted in slow tablet disintegration and dissolution
followed by passage into the intestinal tract.The surprising
finding of prolonged gastric retention prompted study of GI transit
using non-disintegrating, non-erodingplastic caplets in two
additional pigs.
There is a large amount of variability of GI transit with
only two pigs (Table 1.4), but prolonged retention in the stomach
(days rather than hours) occurred consistently for 20
administrations of non-disintegrating plastic caplets just as it
did for the enteric coated magnesium hydroxide caplets in seven
other pigs.Figure 1.4 shows an x-ray photograph of two small size
caplets having low and high density in one of the pigs.The low
density caplet can still be seen in the stomach after 3 days and
the high density caplet is still in the colon after 7 days.Large
size caplets having medium density and dosed on day 0 can be seen
in the small intestine of one pig on day 5 (Figures I.5a and I.5b).
On day 6, it appears to be in the vicinity of the spiral colon
(Figures I.6a and I.6b).These typical X-ray photographs provides18
Table 1.4Transit time in pigs for high, medium, and low density
non-erodible, rigid oral dosage forms having large,
medium, and small sizes
Transit time (days)
Subject Density Gastric Small intestine Large intestine
Large caplet
1 low 1 <1 <1
2
'I
5 <1 >2
1 medium 10 2 19
2
II
5 1 1
It 24a <1 <1
1 high 13 2 4
2 5 2 3
29a <1 >3
Medium Caplet
1 low 4 <1 >1
2 4 <1 >1
1 medium 2 1 3
2
it
1 <1 <1
1 high 7 <1 >3
2
II
5 2 1
Small Caplet
1 low 1 <1 >1
2
II
10 1 1
1 medium 1 <1 <1
2
H
2 1 1
1 high 24 1 1
2
u
3 2 2
arepeat experiment in same animal.Figure 1.4Radiograph of small size caplets inswine.The low
density caplet is in the stomach andthe high density
caplet in the colon (dorso-ventralview).20
Figure I.5aRadiograph of large size caplet in swine.The medium
density caplet is in the small intestine (dorso-
ventral view).Figure I.5bRadiograph of large size caplet in swine.The medium
density caplet is in the small intestine (lateral
view).Figure I.6aRadiograph of large size caplet in swine.The medium
density caplet is in the vicinity of the spiral colon
(dorso-ventral view).23
Figure I.6bRadiograph of large size caplet in swine.The medium
density caplet is in the vicinity of the spiral colon
(lateral view).24
the basis for identification of the specific dosage forms
administered to the pigs and there location in the GI tract with
reliable accuracy.Larger size caplets had longer stomach emptying
times and, therefore, longer total GI transit time.Gastric
emptying time varied from 1'to 28 days and was often between 5 and
20 days for the plastic dosage forms in the two pigs (Table 1.4).
Increase in density was not consistently related to an
increase in gastric emptying time for non-disintegrating caplets,
especially when comparing the medium density and medium size to the
other sizes and densities, as shown in Figure 1.7.Study with more
animals would be necessary to determine if there is a consistent
relationship between increase in density and an increase in stomach
emptying time for non-disintegrating caplets.Such experiments may
be interesting, but would not affect the obvious conclusion that
gastric retention time in pigs is too long for pigs to be a good
model for bioavailability studies involving non-disintegrating
sustained release dosage forms.Small intestine transit time was
consistently less than 3 days and was less than 1 day for 50% of
the doses (Table 1.4).
Non-disintegrating dosage forms were 100% retained in the
stomach for 24 hr or longer in all nine pigs for all dosage forms
studied.All caplets had a diameter of 5 mm-10 mm and density
ranging from 1.25-2.30 gm/mL.Cargill and co-workers recently
found that non-disintegrating flexible silastic disks havinga very
large diameter (25 mm) and a specific gravity of 1.13 were retained25
20-
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Figure 1.7Average gastric residence time in pigs for high-,
medium-, and low-density non-erodible, rigid oral
dosage forms having large, medium and small sizes.26
47% to 67% in the stomach of beagle dogs for 24 hr (13).Smaller
pellets were readily emptied from the stomach.Non-disintegrating
tablets of 3-7 mm diameter and pellets of 0.7-1.7 mm diameter
emptied from the stomach of people in 6 hr or less, depending on
the size of the dosage form and whether the subject was fed or
fasting (14,41-43).It has been suggested that gastric emptying
time of non-disintegrating tablets (3-7 mm diameter) in dogs or
rabbits may be of little or no relevance to man (14).For the
caplets studied herein, gastric emptying in pigs is even less
relevant to man.
Heidelberg capsules were also administered to two pigs (after
about 12 hr of fasting) to measure GI transit and obtain in vivo GI
pH values.Radiographs were used to locate the capsules.
Heidelberg capsules had a gastric residence time in each of two
pigs of >6 days (144 hr), a small intestinal transit time of >2
days, and a large intestinal transit time of >1 day.The gastric
pH varied from 1.15 to 4.0.Two human volunteers also received
Heidelberg capsules in this study after about 12 hr of fasting.
Gastric pH was 1.0-3.8 and gastric emptying time was 2.2-4.0 hr for
the people.The range in gastric pH (in both pigs and humans) may
be attributed to the fact that sometimes the pH capsule works its
way close to the pyloric sphincter, exposing its pH sensing
membrane to duodenal juices.Then, the capsule pops back, i.e. is
retropulsed back into the stomach (18,44).However, the actual
time of leaving the stomach is clearly indicated on the pH27
recording chart or radiograph.28
CONCLUSIONS
It is clear that stomach pH in pigs is similar to man
(17,45), but gastro-intestinal transit time for non-disintegrating
dosage forms is not.Gastric emptying of non-erodible caplets is
found to be much slower in pigs (days) as compared to humans
(hours).Pigs have been reported (18) to possess a interdigestive,
migrating myoelectric complex (MMC), which is known to play an
important and dominant role in the gastric emptying of indigestible
solids in man and dogs.The postprandial activity in pigs fed two
meals/day lasts 2-3 hr and the average number of MMC was 16/day to
18/day in fasting pigs (18).Even though it is possible that some
of the pigs may have been dosed before arrival of the "housekeeper
wave", the number of MMC's during the 8 hr post dosing which occurs
when the stomach is empty should have been sufficient to empty the
caplets from the stomach.However, from this GI transit study, it
seems that such motor activity in pigs is much less efficient in
emptying large indigestible solids from the stomach in comparison
to dogs or humans, or the mechanism in pigs may be entirely
different.The capsule may have emptied with a phase III
contraction, but certainly not the first antral phase III, or it
may have emptied at a time other than phase III activity in the
stomach.Ruckebusch and Bueno (1976) have shown that the
postprandial pattern of electrical activity in pigs is
characterized by almost continuous spiking activity in both the29
antrum and small intestine, lasting 3-6 hours depending on the
volume and number of meals taken per day (18).Strong spike bursts
are superimposed on each slow wave, some being propagated through
the pylorus.The MMC is disrupted completely and occasional strong
spike bursts, isolated or grouped, are propagated from the duodenal
bulb at a high velocity and probably represents peristaltic
activity of the stomach in the digestive mode.This may be
responsible for causing a large object to be emptied randomly from
the stomach.Thus, pigs are not an appropriate animal model for
studying bioavailability or GI transit of non-disintegrating, non-
erodible oral dosage forms.30
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CHAPTER II
ANALYSIS OF VARIABLES INFLUENCING COAT
INTEGRITY FOR CONTROLLING DRUG RELEASE35
ABSTRACT
Temperature and plasticizer effects on coating integrity,
thickness, and drug release were investigated when coating non-
pareil or drug-loaded sugar beads with Aquacoat® using a STREA-1
bench-top spray coating chamber having a 7 inch Wurster column
(Aeromatic Inc., Columbia, MD) mounted on a Lab-Line/P.R.L. Hi-
Speed Fluid-Bed Dryer (Lab-Line Instruments Inc., Melrose Park,
IL).The influence of a processing variable (nozzle orifice
opening) and a few formulation variables (individual vs.
combination plasticizer, or a water-insoluble additive) on
dissolution of a model drug (acetaminophen) spray coated with
Aquacoat® were studied.A combination of coating variables were
identified which produced coated beads with a desirable dissolution
pattern when using the laboratory scale spraycoater.36
INTRODUCTION
Polymeric film coatings are finding an ever-increasingrange
of applications in pharmaceutical research, development, and dosage
form design.Development of controlled-release dosage forms where
the mechanism of drug release is diffusion through polymeric
membrane formed via film coating requires optimization of several
processing and formulation variables to ensure reproducibility of
drug release rate (1).Coat thickness and integrity of the coat
are influenced by many factors including the core/substrate,
coating technique, equipment, nature and type of membrane material,
and formulation employed (1-3).
Coating of substrate cores can be performed in various types
of equipment including coating pans and fluidized beds (4-6) Mehta
et al(1986) showed that the fluidized-bed process using the
bottom-spray method in a Wurster air-suspension column provides
ideal conditions for complete coalescence of polymer particles
(6,7).Solution feeding rate together with atomizing gas pressure
determine degree of atomization of spray, i.e. size and size
distribution of droplets.Perry (1963) showed that the mean
droplet size depends on the volume relation between gas and liquid
(8).Increase in temperature and volume of fluidizing air and
atomizing air pressure increases spraydrying and decreases
substrate agglomeration (1).
Coating formulation variables include type of polymer, nature37
and amount of plasticizer, additives employed, amount of coating
applied, and tack behavior of the coating solution (6,9-11).Until
the mid-seventies, only polymer/organic solvent coating systems
were available.High solvent costs, explosion hazards, potential
toxicity, and strict air-quality controls set by EPA led to the
development of water-based coating systems (5-7,12,13).Latex or
pseudolatex coating systems of water-insoluble polymers offer the
best method of replacing solvent based coatings for extended
release of drugs (13-19).Plasticizers are used in coating
formulations to impart flexibility to a polymer and to promote film
coalescence.One plasticizer useful for ethyl cellulose based on
solubility parameter, intrinsic viscosity, and glass transition
temperature (T9) is diethyl pthalate (DEP) (20-22).However,
dibutyl sebacate (DBS) and triethyl citrate (TEC) are also commonly
used because of low volatility, hence better plasticizer
permanence, and also due to regulatory control (23,24).A complex
three-dimensional relationship has recently been reported among
time to 50% release of coated drug, T9 of plasticizer, and bed
coating temperature with respect to T9 (25).
The purpose of the present study was to optimize parameters
for new laboratory scale coating equipment obtained in our
laboratory.A relationship between coating thickness and drug
dissolution for a single nozzle size has been well documented.
However, such a relationship has not been investigated for
different nozzle sizes.Objectives were to determine temperature38
and plasticizer effects on coat morphology and thickness by
examining coated pellets under a scanning electron microscope
(SEM), and to employ temperature-plasticizer concentrations
identified from this study to evaluate the influence of a
processing variable (spray nozzle orifice diameter) and a few
selected formulation variables on in vitro drug release.39
MATERIALS AND METHODS
TEMPERATURE-PLASTICIZER STUDY
Four different coating formulations (Table II.1) at two inlet
air temperatures (45°C and 75°C) were investigated using a two-
factor factorial randomized block design (26).Aquacoat® [FMC
Corp., Philadelphia, Pennsylvania] was the coating material.
Coating formulations (treatments) consisted of the following (1)
triethyl citrate (TEC) (Morflex Chemical Company, Inc., Greensboro,
North Carolina), (2) dibutyl sebacate (DBS) (Uniflex DBS, Union
Camp Corp., Jacksonville, Florida), (3) dibutyl phthalate (DBP)
(Mallinckrodt, Inc., St. Louis, Missouri), and (4) TEC + DBS.All
plasticizers were added at 30% (based on polymer solids), except
for the combination where 15% of each was added, to Aquacoat® that
had been diluted with deionized water (50:50).Each coating
formulation (adjusted to a total solids content of less than 20% by
adding deionized water) was stirredat least 45 min before
coating, as well as throughout the coating process (Table 11.2).
Each coating formulation, containing 209 gm of diluted and
plasticized Aquacoat® formulation, was applied to 300 gm of 25-30
mesh white, non-pareil sugar pellets (Paular Corp., Princeton Jct.,
New Jersey).Coating mixtures were pumped to the atomizer by a
peristaltic pump (Watson-Marlow 502S, Watson-Marlow Limited,
Cornwall, England) at a rate of 2 mL/min over 18 to 20 minutes to
achieve a seal coat of about 2% solids (w/w) followed by curing for40
Table II.1Aquacoat coating formulations applied to 25-30 mesh
non-pareil sugar beads variable temperature-
plasticizer combinations
No. Temp. TEC DBSDBP Recovery
°C (gm) (gm)(gm) (%)
1 75
45
9.0
9.0
50.0
49.0
2 75 9.0 --- 60.0
45 9.0 55.0
3 75 --- 9.0 52.5
45 --- 9.0 43.0
4 75 4.5 4.5 77.0
45 4.5 4.5 68.0
4a 75 4.5 4.5 --- 91.0
45 4.5 4.5 --- 90.0
aModified coating technique: the perforated steel base pan was
removed fromunder the coating bowl, which results in increased
fluid-bed air flow.
TEC = Triethylcitrate, DBS = Dibutylsebacate, DBP= Dibutyl-
phthalate, and Recovery (%) =based on determining weight of
actual unclumped, individual coated beads vs. weight of total
coated beads.41
Table 11.2Typical processing conditions used for the temperature-
plasticizer study for application of Aquacoat to non-
pareil sugar pellets
Parameter Amount/Setting
Batch size
Nozzle size
Wurster insert
Flow rate
Seal coat (2% w/w)
Final coat (8% w/w)
Inlet temperature
Fluidization air/blower
Atomization air pressure
300 gm
2.5 mm
bottom spray
1.5-2.0 gm/min intermittently
4.0-4.5 gm/min intermittently
75°C or 45°C
50-100% of capacity
10-12 psi
Intermittent delivery was operator controlled as either "on" or
"off" as necessary to control clumping of beads.42
about 20 min, and then at about 5 mL/min in intermittent delivery
to a 10% (theoretical) coating, with a spray nozzle orifice of 2.5
mm.The coating formulation was applied with frequent drying
cycles between intermittent applications as required to prevent
sticking of the beads.Coating with formulation 4 was repeated
delivering an increased volume of air to the fluid bed which was
achieved by removing the perforated steel base plate from under the
coating bowl.
DRUG RELEASE STUDY
1. PREPARATION OF ACETAMINOPHEN (APAP) PELLETS
Hydroxypropyl cellulose (11 gm) (Klucel, Hercules Inc.,
Wilmington, Delaware) and PVP (22 gm) (PVP-40, Sigma Chemical
Company, St. Louis, MO), both used as binders, were dissolved in
1200 mL of ethyl alcohol using a magnetic stirrer.APAP (440 gm)
(Sigma Chemical Company, St. Louis, MO) was dispersed as a
suspension in the binding solution and the total solid content was
adjusted with ethyl alcohol to approximately 30% w/w.Non-pareil
sugar pellets (77 gm) retained in a 25 mesh screen were prewarmed
in the fluid-bed coating chamber at 45-50°C for about 15 minutes.
Spraying of the suspension (7.0 gm/min) containing APAP was
initiated using a 1.2 mm nozzle opening at a nozzle air pressure of
about 10 psi with continuous fluidizing air supply.After all
suspension was applied to provide the desired pellet size43
(% retained only in 12 mesh screen = 97.5%), the pellets were dried
in the chamber using fluidizing air for 30 min at 60°C. They were
then oven-dried overnight (55-60°C) and the final pellets were
found to contain about 1% moisture.
2. ASSAY FOR CONTENT UNIFORMITY OF DRUG-LOADED PELLETS
500 mg of APAP loaded beads were ground into a fine powder.
All powder was transferred into a 1L dissolution flask and stirred
in 900 mL deionized water at 37 ± 0.5 °C for 4 hours.3 mL samples
were collected, filtered, and assayed spectrophotometrically
(Beckman Model 34, Beckman Instruments, Inc., Fullerton, CA 92634)
at 244 nm to determine the content of acetaminophen.At least
three replicate determinations, each using a 500 mg sample of drug-
loaded beads, were made for each batch.
3. COATING OF DRUG BEADS
Variable nozzles used for coating had the following
openings - 2.5 mm, 1.2 mm, 0.8 mm, or 0.5 mm (Aeromatic Inc.,
Columbia, MD).Plasticizers - triethyl citrate and dibutyl
sebacate were added at 30% (based on polymer solids), except for
the combination where 15% of each was added, to aquacoat that had
been diluted with deionized water (50:50).Each coating
formulation (adjusted to a total solids content of 20.5%) was
stirred at least 30 min before coating as well as throughout the
coating process (Table 11.3).The combination plasticizer44
Table 11.3Typical processing conditions for application of
Aquacoat to APAP beads
Parameter Amount/Setting
Batch size 77.0 gm
Nozzle size variable
Flow rate 7.0 gm/min
Inlet and bed temperature 75°C
Fluidization air/blower 50% of capacity
Atomization air pressure 10-12 psi45
formulation was used for coating with all four nozzles.In
addition, the 1.2 mm nozzle was used for coating with individual
plasticizers and combination plasticizer containing 25% talc
(U.S.P. Powder, Matheson Coleman & Bell, East Rutherford, New
Jersey, USA).Coating mixtures, which were continuously stirred
throughout the coating process, were applied to the pellets to
achieve a seal coat of 1% followed by 30 min curing, and then a
second 1% seal coat followed by 30 min curing.The remaining
coating formulation was applied to achieve a final total coating of
6% w/w (theoretical) and cured for another 30 min using fluidized
air.Finally, all coated beads were oven-dried at 55-60°C for
approximately 30 min.
4. IN VITRO DISSOLUTION
In vitro dissolution of each formulation was performed in
triplicate using the USP dissolution apparatus II (Paddle) at 37 ±
0.5°C and at 50 rpm.Dissolution media for the first 2 hr was
enzyme-free simulated gastric fluid (pH = 1.4 ± 0.1), which was
then changed to enzyme-free simulated intestinal fluid (pH= 7.4 ±
0.1).Samples were collected at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0 hr
(in gastric fluid) and 3, 4, 5, 6, 7, 8, 12, 24, 30, 36 and 48 hr
with replacement by an equivalent volume of temperature
equilibrated media.Assay of released drug was conducted
spectrophotometrically at 244 nm.46
SCANNING ELECTRON MICROSCOPY (SEM)
Coated pellets were examined under a scanning electron
microscope (SEM) (Amray 1000A, Amray, Bedford, Massachussets) to
determine morphological differences among applied films.Both
surface (magnification X100, X200, X500, X1000, X2000 and X3500)
and cross-sectional (X100, X200, X500, X1000, X1500 and X2000)
SEM's of coated pellets were obtained.All coated pellets were
cracked in liquid nitrogen and coated with 60:40 gold/palladium
alloy prior to SEM observation of their cross-section, which was
used to measure coating thickness.
In a separate experiment, three different methods of sample
preparation (A, B, and C) for cross-sectional view in SEM were also
investigated.All three methods of sample preparation (A, B, and
C) gave essentially identical results for a 10% (theoretical)
coating level using formulation 4.In method A, samples were
fractured in liquid nitrogen; in method B, samples were sliced with
a sharp surgical blade; and in method C, samples were sliced with a
sharp surgical blade, placed in 100 mL distilled water for 6 hr at
37°C to dissolve the pellet core, then filtered usinga 0.45 Am
membrane filter to collect the coating, and finally air-dried in an
oven for 4 hr.
MATHEMATICAL PREDICTION OF COAT WALL THICKNESS
Coating thickness can be predicted using the equation (27):47
t = (W./W-W.)(P/P.)(d/6)
where t = predicted wall thickness
W. = weight of wall (coating) material recovered
W = weight of coated particles taken
P = density of the encapsulated (core drug bead) particles
P. = density of wall material
d = diameter of the uncoated particle.
The wall thickness of 10% Aquacoat on drug loaded beads is
calculated as follows: P (APAP) = 1.293 gm/cm3, P. (ethyl
cellulose) = 1.13 gm/cm3, 25 mesh uncoated particle size diameter =
710 Am, 30 mesh uncoated particle size diameter = 600 Am (Average =
(710+600)/2 = 655 Am).
Thus, predicted t = (0.1/1-0.1)(1.293/1.13)(655/6) = 13.88 gm
for 25-30 mesh APAP beads.Mathematically predicted coating wall
thickness of 10% aquacoat on 25-30 mesh sugar beads (not containing
APAP) is 14.23 gm.The mathematically predicted thickness range is
from 13.0 to 15.46 Am based on calculations assuming the average
pellet size6, is 671.36 ± 58.85 Am (determined from SEM examination
of 20 uncoated 25-30 mesh sugar pellets).Drug (APAP) loaded
uncoated pellets were much larger and measured 1591 ± 45 Am (n=18).
Therefore, the mathematically predicted average coating thickness
of 6% aquacoat on these larger APAP beads is 19.37 Am and the
thickness range is 18.82-19.91 Am.48
RESULTS AND DISCUSSION
TEMPERATURE-PLASTICIZER STUDY
All three methods of SEM sample preparation(A, B, and C)
gave essentially identicalresults for a 10% w/w (theoretical)
coating using formulation 4 (FiguresII.la, II.lb, and II.1c).In
all cases the coating surface appearanceand thickness are
essentially equivalent.
Analysis of variance showed statisticallysignificant
difference in measured coating thickness atthe a = .05 level due
to formulation or temperature.Also, there is a highly significant
interaction (a = .05) between temperatureand coating formulation.
The mean coating thickness decreasedsomewhat at higher temperature
(75°C), and the change in coating thickness atthe higher
temperature differs a little among typesof coating formulations
(Figure 11.2).Coat integrity appears better andfewer pores were
observed at higher temperature (FiguresII.3a and II.3b).In
cross-section the film appeared more compactand coalesced when
applied at 75°C compared to application at45°C.Average coating
thickness for all applications varied over a rangeof 6.59-13.10
Am, while the mathematicallypredicted average coat thickness was
14.23 gm.This production of less thantheoretically predicted
coating thickness is not surprising as somecoating material is
"lost" to the coating chamber walls andthrough exhaust from the
chamber.Figure II.laDifferent methods of sample preparation for SEM.Method A = samples fractured in
liquid nitrogen.MagnificationX500.Figure II.lbDifferent methods of sample preparation for SEM.Method B = samples sliced with a
sharp surgical blade.Magnification X500.Figure II.lcDifferent methods of sample preparation for SEM.Method C = samples sliced with a
sharp surgical blade, dissolved in 100 mL distilled water for 6 hr at 37°C, then
filtered using a 0.45 pm membrane filter, and finally air-dried in the oven for 4 hr.
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Figure 11.2Effect of temperature and type of coating formulation
(see Table II.1) on coat thickness.(0) = 45°C and
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The recommended product bed coating temperature for Aquacoat®
plasticized with these plasticizers is about 40-45°C, based on
glass transition temperature measurements performed by FMC (Food
and Pharmaceutical Products Division, Princeton, NJ).Thus, the
75°C air inlet/bed temperature is well above the glass transition
temperature for all formulations used in this study.While this
higher temperature may result in uncontrolled clumping in large
commercial spray coating operations, it was manageable and produced
excellent coats in the laboratory spray coater.
Comparison of coating with and without a base plate to modify
air flow using formulation 4 showed significant differences between
mean coating thickness at low and high temperatures, and between
the two different air flows at the a = .01 level (Figure 11.4).
Removal of the base plate resulted in increased air-flow and an
increased mean coating thickness from 11.96 Am to 14.84 Am at 45°C,
and from 9.89 gm to 11.77 Am at 75°C.Thus, the increased air flow
may have increased the fraction of atomized Aquacoat® applied to
the target pellets and decreased the amount lost to the coating
chamber walls and exit air.Alternatively, one could theorize that
increased air flow may have produced a thicker but less dense or
"spongy" coating layer due to incompletely coalesced
ethylcellulose.However, under SEM the coats appeared to be
equally dense and well coalesced suggesting that increasing airflow
is an advantage in the system used.It also considerably increased
the % recovery of coated pellets, i.e. the high fluidizing air-flow20
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Figure 11.4Effect of base plate on coat thickness. (0) = 45°C and
() = 75°C.57
reduced sticking and clumping of beads.The mean coating thickness
was higher for both air flows at 45°C compared to 75°C.
DRUG RELEASE STUDY
A typical SEM photograph of whole coated bead is shown in
Figure 11.5.The cross-section of a coated bead shows three
distinct layersthe inner sugar core, the middle layer of
acetaminophen, and the outer coating layer (Figure 11.6).SEM
photographs of cross-sections of coated APAP drug pellets reveal
the film to be compact and coalesced, with a coating thickness
range for all applications between 9.06 and 14.65 Am although the
theoretical coating thickness range is 18.82-19.91 Am. SEM revealed
a greatly decreased number of pores were observed with the smallest
nozzle orifice opening (Figures II.7a, II.7b, II.7c, and II.7d).
In vitro dissolution of APAP from coated pellets was slowest when
the coating was applied with the smallest nozzle orifice opening
(0.5 mm), and fastest for the largest nozzle (2.5 mm) as shown in
Figure 11.8.The 2.5 mm nozzle produces a coat with about 30% more
pores than the 0.5 mm nozzle as observed by SEM.This explains why
the time for 50% drug dissolution (d50%) for the 0.5 mm nozzle is
about 3 times larger than that of the 2.5 mm nozzle, even though
the coating percentage by weight is the same and the coating
thickness is essentially identical.
For this laboratory spray coater, an increase in nozzle
orifice size results in an increase in aerosol droplet size,Figure 11.5Typical SEM photograph of whole coated bead.Magnification X50.Figure 11.6Typical SEM photograph of cross-section of coated bead showing threedistinct layers
inner sugar core, middle drug layer, and outer coating layer.Magnification X100.Figure II.7aEffect of nozzle size on coat morphology.2.5 mm nozzle.Magnification X1000.
[Formulation 4 (See Table II.1), Temperature 75°C)].Figure II.7bEffect of nozzle size on coat morphology.1.2 mm nozzle.Magnification X1000.
[Formulation 4 (See Table II.1), Temperature 75°C)].Figure II.7cEffect of nozzle size on coat morphology.0.8 mm nozzle.Magnification X1000.
[Formulation 4 (See Table II.1), Temperature 75°C)].Figure II.7dEffect of nozzle size on coat morphology.0.5 mm nozzle.Magnification X1000.
[Formulation 4 (See Table II.1), Temperature 75°C)].40
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Figure 11.8Effect of nozzle orifice on coat thickness and drug
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thereby producing a slower drying andmore permeable film.Smaller
aerosol droplets produced by smaller nozzles resultedin a better
water evaporation to droplet coalescence ratio, which producesa
less porous (but approximately equal thickness) film whenusing the
particular chamber and nozzle design of this laboratoryspray
coater.Such a relationship would translate intoa reduced amount
of coating needed, and therefore lower processing cost andtime
when using the smaller nozzle, if these results hold withlarge
scale production equipment.If optimization of water-evaporation-
to-droplet-coalescence ratio already exists ina commercial
operation, then use of smaller nozzles may not be beneficial.
Usually the most important feature ofa nozzle is the size of the
aerosol droplet it produces, with fine drops being favored(8).
Aulton and Banks observed that a larger nozzle producesa larger
droplet (28).
TEC is most efficient in producing slower APAP release,
followed by the combination plasticizer, while DBSwas the least
efficient (Figure 11.9).The hydrophobic powder (talc), increased
drug release from coated beads (Figure II.10).This finding is
consistent with the results of Ghebre-Sellassie et al., 1986-87who
reported that water-insoluble additives like talc, kaolin,and
magnesium trisilicate, when incorporated into Eudragit E-30D
formulations, increased drug release from coated beads.The rank
order of plasticizer used in this study to decrease invitro
dissolution and improve film morphology is TEC> TEC + DBS > DBS.40
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Figure 11.9Effect of plasticizer on coat thickness andon drug
release using a nozzle orifice of 1.2mm.(o) = coat
thickness and () = time to 50% dissolution.Standard
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of 1.2 mm.(o) = coat thickness and )= time to
50% dissolution.68
Thus, combination plasticizer can be used to modify drug release.
Incorporation of a water-insoluble additive reduces tackiness of
the coating formulation as well as modifying release.69
CONCLUSIONS
It is desirable to coat in the Aeromatic laboratoryspray
coater at an inlet temperature higher than the recommended coating
temperature of 40-60°C for Aquacoat® plasticized with DBS, DBPor
TEC because coat integrity improved with increasing temperature and
fewer pores were observed.Smaller nozzle openings provide
coatings which produce slower drug release and films with fewer
surface imperfections with this equipment.More effective coats
were obtained when air flow through the chamber was increased by
removing a air diffusing base plate.Coat integrity rather than
thickness of the coat is most important in controlling drug release
for conditions studied here-in.It is important to note that this
specific coating equipment is for small scale operation and
findings from this current study may not be of value for scale-up,
but may serve as a guideline to other labs as they firstuse new
laboratory scale coating equipment.70
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CHAPTER III
PHARMACOKINETICS AND PHARMACODYNAMICS IN ACETAMINOPHEN
CONTROLLED RELEASE DOSAGE FORM DESIGN74
ABSTRACT
Relationships between pharmacodynamics (drug concentration
and effect) and pharmacokinetics were used to developan oral
controlled release beads molded into a tablet dosage form.
Reported pharmacodynamic data were utilized with pharmacokinetic
curves to identify effective therapeutic drug concentration for
optimum therapy for a drug with a "deep tissue" effective
compartment.The commonly used over-the-counter (OTC) non-narcotic
analgesic-antipyretic, acetaminophen (APAP) was usedas the model
drug.Data reported in the literature were compared for analgesic
and antipyretic efficacy.Computer simulations were performed
using MAXSIM® (Version 3.01) to suggest a zero-order drug release
useful for a 12 hr oral sustained dosage form for analgesic-
antipyretic therapy in both children and adults basedon current
dosing of APAP.Simulations were performed to steady state usinga
dual, unequal input function for each dose.Coated APAP beads with
the desired release rate were then developed using fluid-bed
coating technology.These beads were then formulated into a molded
tablet.The controlled release APAP molded tabletwas administered
to a adult human volunteer as a preliminary evaluation.In vitro
and preliminary in vivo results indicate that sustained therapeutic
acetaminophen concentrations are possible using the newly developed
acetaminophen molded tablet dosage form.75
INTRODUCTION
The time course of drug concentration in the body is defined
by its pharmacokinetics, and the study of concentration-effect
relationships is known as pharmacodynamics.One approach to drug
design and optimized therapy involves combining pharmacodynamics,
pharmacokinetics, and tailored dosage form design for individual
drugs.This approach may help maximize therapeutic efficacy and
correspondingly reduce adverse effects.Further, a significant
limitation in oral controlled release dosage forms is the size of
the dose to be administered in order to maintaina therapeutic
response.This is especially important for relatively large dose
drugs.Combining pharmacodynamics and pharmacokinetics to
accurately predict optimum dose may allow lowering the total daily
drug dose in controlled release dosage forms relative to multiple
single doses.
The purpose of this study was to apply pharmacodynamic and
pharmacokinetic information for a model drug to developa dosage
form with a 12 hr sustained release for oral administration.The
commonly used over-the-counter (OTC) non-narcotic analgesic-
antipyretic, acetaminophen (APAP) was usedas the model drug.
Concerns about Reye's syndrome associated with salicylateuse have
resulted in APAP becoming one of the safest and most widelyused
analgesic-antipyretics in children (1-5).Controlling and
prolonging release of therapeutic concentrations would likely76
extend antipyresis and analgesia, thereby decreasing the required
frequency of administration.However, the dose is large, t112 is
short (2-3 hr), and pharmacodynamics must be well understood to
minimize the controlled release dose while maintainingan effect.77
MATERIALS AND METHODS
COMPUTER SIMULATIONS
Computer simulations were performed using MAXSIM®(version
3.01, Uppsala, Sweden) assuming a 12 hr oral controlledrelease
dosage (zero-order release) for therapy in 2-3yr old children,
based on current pediatric dosing within the currentOTC labeling
of doses (6).Pharmacokinetic parameters of APAP in febrile
children who received a 10 mg/kg dose of elixirare listed in Table
III.1.The parameters and their values (Table III.1) usedfor this
simulation are: Ka = 3.25 hr..% T1/2 1.8 hr, F = 0.9, Ket = 0.385
hr-1, and Vd= 0.86 L/kg.Simulations were also performed for
adults using two compartment open model pharmacokineticparameter
values derived from oral administration ofa single dose of 325 mg
Tylenol tablet (7).The parameters and their values used for this
simulation are: Ka = 9.74 hr'1, T1/2 2.7 hr, F = 0.9,Ket = 0.522
hr-1, Vd= 0.9 L/kg, K12 = 0.697 hr-1, and K21 = 1.22 hr-1.
SUSTAINED ACTION APAP BEAD PRODUCTION
Polymer film coating technologywas used to produce
controlled release (sustained action) acetaminophen pellets.The
coating apparatus consisted of aspray coating chamber having a
seven-inch Wurster column (STREA-1, Aeromatic Inc.,Columbia,
Maryland) mounted on a fluid-bed dryer (Lab-Line/P.R.L.Hi-Speed
Fluid-Bed Dryer, Lab-line Instruments Inc., MelrosePark, Illinois).Table III.1One compartment open model pharmacokinetics of APAP in febrile children
Age Cmax Tmax T112 lcI Vd Kabs Reference
(yrs)(Ag/mL) (hr) (hr) (hr-1) (L/kg)(hr.)
1.7-6 8.0 0.5-11.8 0.3851-1.2 ---Peterson et al (8-10)
2.0-7 9.3 0.7 1.8 0.3760.86 3.25Wilson et al(11)
2.0-11 6.8 0.9 1.8 0.39 2.20Walson et al(12)79
Thermometer readings have shown that, with this fluid bed dryer air
supply, the inlet temperature and bead bed temperatureare
identical.Ethyl cellulose (Aquacoat ®, FMC Corp., Philadelphia,
Pennsylvania) was used as the coating material.Two plasticizers
were used: triethyl citrate (TEC) (Morflex Chemical Company Inc.,
Greensboro, North Carolina) and dibutyl sebacate (DBS) (Uniflex
DBS, Union Camp Corp., Jacksonville, Florida).Previously
optimized processing and formulation variables for the laboratory-
scale fluid-bed coating system were used in this study (13, Chapter
II).
APAP PELLET FORMULATION
Hydroxypropylcellulose (Klucel, Hercules Inc., Wilmington,
Delaware) and polyvinylpyrrolidone (PVP-40, Sigma Chemical Company,
St. Louis, Missouri), both used as binders, were dissolved in 95%
ethyl alcohol using a magnetic stirrer.APAP (Sigma Chemical
Company, St. Louis, Missouri) was dispersed as a suspension in the
binding solution and the total solid content adjusted to about 30%
w/w.Sugar pellets passing through a 20 mesh and retained ina 25
mesh screen were prewarmed in the fluid-bed coating chamber at 45-
50°C for approximately 15 minutes.Spraying of the suspension (7.0
gm/min) containing APAP was initiated usinga 1.2 mm nozzle opening
at a nozzle air pressure of about 10 psi with continuous fluidizing
air supply.After all suspension was applied to provide the
desired pellet size (percentage retained only in 10 meshscreen =80
92.6%), pellets were dried in the chamber using fluidizing air for
30 min at 60°C.They were then oven-dried overnight (55-60°C) and
the final pellets found to contain about 1% moisture.A separate
batch of APAP loaded sugar beads were produced in a similarway but
using a 0.8 mm nozzle opening.
DRUG LOADING ASSAY
500 mg of APAP-loaded beads were ground into a fine powder.
All powder was transferred into a 1L dissolution flask and stirred
in 900 mL deionized water at 37 ± 0.5 °C for 4 hours.Then 3 mL
samples were collected, filtered, and assayed usinga
spectrophotometer (Beckman Model 34, Beckman Instruments Inc.,
Fullerton, California) at 244 nm to determine the content of
acetaminophen.At least three replicate determinations, each using
a 500 mg sample of drug-loaded beads, were made for each batch.
Drug loaded beads used for immediate release, 2.5%, 3%, and 1%, 2%,
3.5%, 4% and 6% Aquacoat coated controlled release beadswere found
to contain approximately 74.82 ± 0.663% (SD), 79.60 ± 0.88%, 71.68
± 0.65%, and 68.67 ± 1.83% APAP.
POLYMER COATED BEADS
Water-based polymeric films were applied to acetaminophen
bead cores to provide rate-controlling membranes.Plasticizers
(TEC and DBS) were combined and added at 30% (15% each, basedon
polymer solids), to Aquacoat® that had been diluted with deionized81
water (50:50).The coating formulation (adjusted to a total solids
content of about 20%) was stirred at least 30 min before coating
and throughout the coating process (Table 111.2).Coating mixtures
were applied to the pellets to achieve a seal coat of 1% for
coating levels >1% and was followed by 30 minutes of curing with
fluidized air.The remaining coating formulation was then applied
to achieve the final percentage (theoretical) coat and cured for
another 30 min using fluidized air.Finally, all coated beads were
oven-dried at 55-60°C for about an hour.Coating levels
(theoretical) applied to APAP loaded beads using a 1.2mm nozzle
opening and a 0.8 mm nozzle opening consisted of 1%, 2%, 3%, 3.5%,
4% or 6%, and 2.5% respectively.Actual weight gain due to coating
was less due to coating loss on the chamber walls and out the
exhaust.
MOLDED TABLET DOSAGE FORM PRODUCTION
The ingredients listed in Tables 111.3, 111.4, and 111.5were
individually combined by geometric dilution.The mixed ingredients
were moistened with water.All ingredients used in the manufacture
of this test tablet meet United States Pharmacopeia guidelines for
safety and efficacy, and are common, non-toxic ingredients used
routinely in tablet manufacture.The custom made hand molding
apparatus used for making the molded tablets consists of two plates
made from plastics (Figure III.1).The mold plate contains 24
polished perforations.The other plate is fitted with a82
Table 111.2Typical processing conditions for Aquacoat® coated
APAP pellets (STREA-1, Aeromatic)
Parameter Amount/Setting
Batch size 100 gm
Nozzle size 0.5 mm
Flow rate 4-6 gm/min
Inlet temperature 75 °C
Fluidization air/blower 5
Atomization air pressure 10-12 psi83
Table 111.3Composition of molded tablet for acetaminophenpellets
(Formulation 1)
Ingredient Weight (mg)
Uncoated immediate release beads (250mg APAP) 334.0
3% Aquacoat beads (750 mg APAP) 1079.0
Mannitola 687.0
Ac -di -solo 150.0
Total weight 2250.0
a Mannitol powder, J.T. BakerChemical Co., Phillipsburg, NJ 08865.
b
Modified cellulose gum, FMC Corp., Philadelphia,PA 19103.84
Table 111.4Composition of molded tablet for acetaminophenpellets
(Formulation 2)
Ingredient Weight (mg)
Uncoated immediate release beads (200mg APAP) 268.0
3% Aquacoat beads (750 mg APAP) 1079.0
4% Aquacoat beads (250 mg APAP) 380.0
Mannitola 723.0
Ac -di -solo 150.0
Total weight 2600.0
a
Mannitol powder, J.T. Baker Chemical Co.,Phillipsburg, NJ 08865.
b
Modified cellulose gum, FMC Corp., Philadelphia,PA 19103.85
Table 111.5Composition of molded tablet for acetaminophen pellets
(Formulation 3)
Ingredient Weight (mg)
Uncoated immediate release beads (200 mg APAP) 268.0
2.5% Aquacoat beads (750 mg APAP) 966.0
4% Aquacoat beads (250 mg APAP) 380.0
Mannitola 736.0
Ac -di -solo 150.0
Total weight 2500.0
aMannitol powder, J.T. Baker Chemical Co., Phillipsburg, NJ 08865.
bModified cellulose gum, FMC Corp., Philadelphia, PA 19103.86
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Figure III.1Hand molding apparatus used for making molded tablets.87
corresponding number of punches which fitthe perforations in the
mold plate.The mold plate is placedover the plate with the
corresponding pegs and the wetmass for each tablet are then gently
forced into the perforations and theexposed surface smoothened
with a spatula.The mold apparatus was placed inan air-dried oven
at 55°C for about 10 minutes and thentaken out.As hand pressure
was applied to the plates, the pegs forced the tabletout of the
mold (Figure III.1).The ejected tablets were placedon individual
glass petri-dishes and dried in theoven for an additional 50
minutes.
The molded tablet has been designedto disintegrate into
individual beads in thepresence of saliva in 30-40 seconds.If
needed, small amounts of watercan be taken to facilitate
disintegration.The individual beads are to beswallowed intact,
without chewing.Children and the elderly, andsome normal adults
may have chewing or swallowing difficulties whengiven solid oral
dosage forms (tablets or capsules),especially drug delivery
systems containing a large dose ofactive ingredient like
acetaminophen.Hence, the molded tablet dosage formwould be for
such a patient population.If the coated beadsare chewed or
crushed, all sustained releaseproperties are lost.
PRELIMINARY IN VIVO STUDY
The molded tablet formulations (1and 2) listed in Tables
111.3 and 111.4 were administeredto one healthy, adult human88
volunteer after obtaining written informedconsent.Each treatment
consisted of two molded tablets containinguncoated immediate
release beads and coated sustained releaseacetaminophen beads
given once every 12 hours fora total of two doses.After the
molded tablets disintegrated into individualbeads, they were to be
swallowed intact, without chewing.Treatments were taken on two
separate occasions with a wash-out periodof at least 4 days.The
subject fasted 12 hours prior to, and2 hours after the first dose
for each treatment.Fasting was observed 2 hours priorto, and 2
hours after the second dose.During the fasting periodno food or
beverage other than water was consumed.
The molded tablets were taken with 6oz. of water immediately
followed by a thorough mouthwash rinsewith 3 oz. of Scope@
(Proctor and Gamble, Cincinnati, OH)to help wash away residual
drug concentration in the oral cavity.Saliva samples were
collected in 12 mL glass centrifuge tubesover a one minute period
by chewing on Parafilm (AmericanCan Co., Greenwich, CT)squares
(2.5 cm X 2.5 cm) to induce salivasecretion.Samples were
collected according to the followingschedule: 0 hour (just prior
to first dose and second dose with eachtreatment), and then 10,
20, 30, 45 minutes, 1, 1.5, 2, 2.5,3, 4, 6, 8, 12, 16, and 24
hours after the second dose.Samples were covered with Parafilm
and refrigerated immediately aftercollection.
Saliva samples were frozen at -20°C,thawed, and centrifuged
(Beckman Model TJ-6 Centrifuge, PaloAlto, CA) at 3000 rpm for 3089
minutes to remove mucous and particulatematter.Salivary
supernatant was removed and transferredto a 2.5 mL polypropylene
Cryo-Stor screw-cap vials (PerfectorScientific, Inc., Atascadero,
CA) and stored at -20°C untilanalyzed.These were again
centrifuged prior to HPLC analysis.
SALIVA ACETAMINOPHEN HPLC ASSAY
Saliva acetaminophen concentrationswere determined using a
modification of an HPLC method used byBonin (7).Stock solutions
containing 20, 50, 100, 200, 300, 400,500, 600, 800, 1000, 1200,
and 1500 gg/mL of acetaminophen(Sigma Chemical Co., St. Louis,MO)
were prepared in distilled, deionized water.An 80 gg/mL solution
of 2-acetamidophenol (Sigma ChemicalCo., St. Louis, MO) in
distilled, deionized waterwas used as the internal standard.
Standards were prepared by spiking500 AL of blank saliva with 25
AL of the above stock solutions.100 gL of standardor unknown was
mixed with 100 AL of internalstandard solution ina 250 AL
polyethylene centrifuge tube andvortexed for 20 seconds.
Saliva acetaminophen concentrationswere determined by an
HPLC system consisting ofa delivery pump (M-6000A, Waters
Associates, Milford, MA),an automatic sample injector (WISP 712B,
Waters Associates, Milford, MA),a C-1308 guard column with
Perisorb® RP-18 packing material(Upchurch Scientific, Inc., Oak
Harbor, WA), a 4.6 mm X 25cm reverse phase Zorbax Pro-10 C8
analytical column (Part No. 884988-902,Du Pont Company,90
Wilmington, DE), a fixed wavelength UV detector(Model 440, Waters
Associates, Milford, MA) set at 254im, and an integrator (C-R3A
Chromatopac, Shimadzu Corp., Kyoto, Japan).
Mobile phase consisted of 10% (v/v) methanol(ChromAR© HPLC,
Mallinckrodt Inc., Paris, Kentucky) indistilled, deionized water
at a flow rate of 2.5 mL/min.Injections of 10 gL were made with
the UV absorbance detector set at0.005 AUFS sensitivity.
Integrator attenuation and chart speedwere 5 and 6 mm/min
respectively.Retention times were 2.6 minutes foracetaminophen
and 3.4 minutes for 2-acetamidophenol.
Peak area ratios of acetaminophen:internalstandard versus
standard concentrationswere fit to a straight line via simple
linear regression.Standard curves were prepared daily with
excellent coefficients of determination, R2> 0.999.The
coefficient of variation varied from 4.53to 7.15% over the range
of 0.95 to 47.62 gg/mL of acetaminophen.The sensitivity of the
assay was approximately 1 gg/mL.
IN VITRO DISSOLUTION
In vitro dissolution of each formulationwas performed in at
least triplicate using the USP dissolutionapparatus II (Paddle) at
37 ± 0.5°C and 50 rpm.Dissolution media for the first 2 hrwas
enzyme-free simulated gastric fluid (pH= 1.4 ± 0.1), which was
then changed to enzyme-free simulatedintestinal fluid (pH= 7.4 ±
0.1).Samples were collected at 0.25, 0.5,0.75, 1.0, 1.5, 2.0 hr91
(in gastric fluid) and 3, 4, 5, 6, 8,12, 24, 30, 36 and 48 hr with
replacement by an equivalent volume oftemperature equilibrated
media.Assay of released drug was conductedspectrophotometrically
at 244 nm.
AGEING STUDY FOR MOLDED TABLET
Molded tablets produced using formulation2 and 3 (Tables
111.4 and 111.5) were placed in smallair-tight glass bottles and
stored in an air-driedoven at 37°C.In vitro acetaminophen
dissolution from these molded tabletswere determined after one
day, one week, and one month.The unmolded formulationswere used
as a control.92
RESULTS AND DISCUSSION
PHARMACODYNAMIC-PHARMACOKINETIC EVALUATION
An across studies comparison of literaturedata for analgesic
and antipyretic effects of acetaminophencompared to plasma drug
concentrations was conducted.Pharmacodynamic curves were
superimposed on pharmacokineticcurves to determine effective
therapeutic drug concentration for optimumtherapy (12,14-17).A
minimum plasma concentrationrange of about 3-5 ag /mL produces
maximum analgesic-antipyretic effect infebrile children when
administered as a single oral dose of10 mg/kg (Figures 111.2 and
111.3).Wilson et al(1982) also reported a Cmin of 4 gg/mLand
C.. of 18 gg/mL for maximum antipyreticeffect in a similar
population (11,18).Temperature reduction is reported to be
continued or maintained as longas plasma levels exceed 5 gg/mL
(10).As drug levels declined post peak,both analgesic and
antipyretic efficacy continued to increaseuntil equilibriumwas
established between the centralcompartment and a deep tissue
effective compartment (Figure 111.4).In Figure 111.4, effect-
concentration data points are connectedin order of decreasing time
one hour after maximum plasma concentration.These data suggest
the plasma concentration of APAPmay decline to as low as about 2
gg/mL post-peak concentration withvery little loss in antipyretic
effect.It has been suggested that receptorsfor antipyresis are
either not in the central compartmentor they are in deeperC71
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Figure 111.2Antipyretic effect of acetaminophen in febrile
children (dose = 10 mg/kg). () plasmaconcentration
(ref. 12),(o) mean temperature decrement (ref. 12),
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Figure 111.3Analgesic effect of acetaminophen in febrile
children (dose 10 mg/kg).(0) plasma concentration
(ref. 12),(0) pain intensity difference and (o)
pain relief score (both ref. 14).64.0 0
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Figure 111.4Analgesic-antipyretic effect of acetaminophen in
febrile children.Effect-concentration data points
are connected in order of decreasing time 1 h after
maximum plasma concentration. (0) and (o)pain
intensity difference and pain reliefscore
respectively (ref. 14), (0)mean temperature
decrement (ref. 12), (A) mean temperaturedecrement
(ref. 16), (v) mean temperaturedecrement (ref. 15),
and () mean temperature decrement(ref. 17).96
portions of organs (i.e. brain) associatedwith that organ (18).
A plot of plasma APAP concentration againstantipyretic
effect in sequence by increasing time showsan anticlockwise
hysteresis loop (Figure 111.5).This indicates equilibration delay
between plasma concentration and theeffective site producing the
antipyretic effect (19).Such a hysteresis loopmay be
"eliminated" by plotting effectvs. drug concentration in another
compartment of the model (tissue concentration).Recently, the
concentration of APAP in plasma and cerebrospinalfluid (CSF) was
measured simultaneously in humans, and APAPwas found to cross the
blood-brain-barrier fairly rapidly (20).The concentration curve
in the CSF was suggestive of the analgesiceffect curve of APAP.
The total dose selected fora 15 kg child (380 mg) was
divided to consist of an immediate releaseportion of 80 mg and a
sustained release portion of 300mg (ko = 25 mg/hr for 12 hours),
and is slightly less than the maximumamount (400 mg) allowed to be
administered in 12 hours (6).Simulation predicts the plasma drug
concentration will be maintained above 5 Ag/mL(Figure III.6a)
which will produce maximum analgesic-antipyreticeffects for the
entire dosing interval.A usual dose of 160 mgevery 6 hours
allows plasma concentrations to decreasebelow 5 gg/mL about 56% of
the time each day (Figure III.6b).If a Cfmn of only 2 tig/mL is
acceptable for antipyresis (Figure 111.4),then the dose could be
reduced with the proposed dosage form,but not with the usual
immediate release product.Simulated acetaminophen concentration-a1.6
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Figure 111.5Counterclockwise hysteresis loop betweenplasma
concentration and antipyretic effect plottedin order
of increasing time. (0)mean temperature decrement
(ref. 12),(A) mean temperature decrement (ref.16),
and (v) mean temperature decrement(ref. 15).E
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Figure III.6aMaxsime computer simulation of plasma acetaminophen
concentration in 2-3 year old children.Immediate
release portion of 80 mg and sustained release
portion of 300 mg (total dose= 380 mg) given every
12 hours.99
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Figure III.6bMaxsim® computer simulation of plasma acetaminophen
concentration in 2-3 year old children.Usual
immediate release dose of 160mg given every 6
hours.100
time profiles for adults receiving two moldedtablets of
formulation 1 (Table 111.3) and two moldedtablets of either
formulation 2 or 3 (Tables 111.4 and 111.5)shows maintenance of a
minimum concentration of about 4 gg/mL (FigureIII.7a) and 5 gg/mL
(Figure III.7b) respectively.In comparison, the usual adult dose
of 1000 mg given every 6 hours allowsplasma acetaminophen
concentrations to decrease below the minimumeffective
concentration (>5 gg/mL) about 70% of the timeeach day (Figure
III.7c).
IN VITRO DISSOLUTION OF SPRAY-COATEDACETAMINOPHEN PELLETS
APAP dissolution profiles from beadstheoretically coated
with 1%, 2%, 3% and 6% ethyl cellulose(Figure 111.8) prompted
production of 3.5% and 4% coatings (Figure111.9).Simple linear
regression of dissolution data for 3%, 3.5%and 4% coatings (Figure
III.10) revealed the 3% coating approximatelyproduced the desired
zero order release (Table 111.6) over 90% of the releaseprofile.
A plot of drug release rateversus theoretical amount of Aquacoate
applied shows that a minimum coating levelof 2% w/w is required to
produce sustained release (Figure III.11).Also, coating above 2%
w/w resulted in a nearly linearrelationship for drug release for
the drug and conditions investigated.
WALL THICKNESS OF SPRAY-COATED ACETAMINOPHENPELLETS
Thickness of encapsulating material hasbeen previously10.0000-
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Figure III.7aMaxsirn® computer simulation of plasmaacetaminophen
concentration in adults.Immediate release portion
of 500 mg and 3% Aquacoat sustained releaseportion
of 1500 mg (total dose= 2000 mg) given every 12
hours.10.0000.
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Figure III.7bMaxsimo computer simulation of plasma acetaminophen
concentration in adults.Immediate release portion
of 400 mg APAP combined with 3%or 2.5% Aquacoat
coated sustained release portion of 2000mg APAP
(total dose = 2400 mg) givenevery 12 hours.20.0000
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Figure III.7cMaxsime computer simulation of plasmaacetaminophen
concentration in adults.Usual immediate release
dose of 1000 mg given every 6 hours.104
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Figure 111.8Dissolution profile of acetaminophen beads coated
with Aquacoat ®.Standard deviation error bars are
shown except in those case where theyare smaller
than the symbol.100
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Figure III.10Simple linear regression fitting of dissolution
data.
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Table 111.6Effect of coating levelon APAP release rate
Coating Amount Released (mg/hr) R2
1.0% 146.7 0.858
2.0% 46.4 0.989
3.0% 23.0 0.993
3.5% 19.8 0.987
4.0% 16.9 0.983
6.0% 6.2 0.992160
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Figure III.11Effect of coating amount on acetaminophen release
rate.109
evaluated (21) and wall thickness calculationsfor coated APAP
beads have been reported earlier (13).APAP-loaded uncoated
pellets measured 1766 ± 70Am (n = 20).Mathematically predicted
and measured coating thickness for each ofthe coating levels are
given in Table 111.7.A plot of coat wall thickness and time
to 50% dissolution vs. amount of coat theoreticallyapplied (Figure
111.12) shows, as expected, that all threeare interrelated and
correlate with each other.Data in Table 111.7 suggest that actual
coating wall thickness is only about one-halfof the theoretical
wall thickness in mostcases.The production of less than
theoretically predicted coating thicknessis not surprising,
because some coating material is lostto the coating chamber walls
and through exhaust from the chamber.Assay of coated pellets
using weight gain to give actual percentcoat applied revealed
about 45-76% of the theoretical coat beingdeposited.Statistical
analysis of observed coat thickness andtime to 50% dissolution
(d50x) was performed usingone-way analysis of variance (ANOVA) and
Least Significant Difference (LSD) formultiple comparisons.As
expected, one-way ANOVA revealed highlysignificant differences (p
< 0.01) in observed coat thickness and d50mamong coating levels.
Pairwise comparisons amongmean observed thickness and among mean
d50m revealed significant differencesat p < 0.05.
BATCH TO BATCH COMPARISONS
Coating of APAP loaded beads with 3%Aquacoat was repeated to110
Table 111.7Effect of coating on coat thickness' anddrug release
Coating
Coat Thickness
Theoretical (Am) Observed (iim)b d50% (hr)b
1.0% 3.40 0.86± 0.12 0.43 ± 0.07
(3.27-3.54)
2.0% 6.87 3.16± 0.85` 2.42 ± 0.14
(6.60-7.14)
3.0% 10.42 4.37± 0.63'd 5.25 ± 0.25
(10.01-10.83)
3.5% 12.22 5.95± 6.42 ± 0.38
(11.73-12.70)
4.0% 14.03 7.44± 0.94' 9.75 ± 0.25
(13.48-14.59)
6.0% 21.50 12.21± 2.70 26.42 ± 1.24
(20.65-22.35)
a Average ± SD. Values inparenthesis are ranges.
b
Multiple range test for observedmeans using LSD at p = 0.05;
differences between means sharinga common alphabet are not
statistically significant.Observed coat thickness was measured
for a minimum of 3 samples using scanningelectron microscopy as
previously reported (13).30
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Figure 111.12Effect of actual coat thicknesson time to 50%
dissolution (d50%) of acetaminophen.112
ensure reproducibility of the coatingprocess.Dissolution
profiles for these two different batchesof 3% Aquacoat are very
similar (Figure III.13a) and simple linearregression of the
dissolution data provided essentiallyidentical slopes (Figure
III.13b). The 2.5% coating (also repeatedtwice) showed identical
dissolution profiles andwere also surprisingly similar to that of
the 3% coating (Figure III.14a).Linear regression of the
dissolution data for the 2.5% coat and3% coat gave quite similar
values for the slope (Figure III.14b).Scanning electron
microscopy (discussed in Chapter II) of theuncoated APAP loaded
beads revealed significant morphologicaldifferences between the
beads produced using a 1.2mm nozzle opening (Figure III.15a)
versus a 0.8 mm nozzle opening (Figure III.15b).The 0.8 mm nozzle
produced more spherical beads with lesssurface imperfections and
cavities.These beads when coated toa 2.5% level gave identical
dissolution profile as the 3% coat.Coat wall thickness
measurements of these beads using scanningelectron microscopy
revealed very similar coat thicknesses(3.75 ± 1.38 gm for the 2.5%
coat and 4.37 ± 0.63 gm for the 3% coat).This would explain why
these two different coating levelsstill provided quite similar
dissolution profiles.Importance of substrate morphologyon drug
dissolution from coated beads has beenreported by Mehta (22).
IN VITRO DISSOLUTION OF MOLDED TABLETS
Dissolution of APAP from molded tabletsproduced using100
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Figure 111.13aDissolution profile of two different batchesof 3%
Aquacoat® (AQ) pellets.100
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Figure III.13bSimple linear regression of dissolutiondata of two
different batches of 3% Aquacoat® (3% AQ-Iand 3%
AQ-II).100
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Figure III.14aDissolution profile of two different batchesof
2.5% Aquacoato (AQ) pellets and 3% Aquacoate(AQ).120
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Figure III.14bSimple linear regression of dissolution data of two
different batches of 2.5% Aquacoat® (AQ) and 3%
Aquacoat® (AQ) coated beads.117
Figure III.15aScanning electron micrograph of uncoated APAP
loaded bead produced with a 1.2 mm nozzle opening.
Magnification X50.118
Figure III.15bScanning electron micrograph of uncoated APAP
loaded bead produced with a 0.8 mm nozzle opening.
Magnification X50.119
formulation 3 (Table 111.5)appears slightly faster than from the
unmolded formulation (Figure III.16a).The slight increase in
dissolution rate (Figure III.16b)may be due to the tablet molding
process, which involves moistening of the pelletswith water and
mixing with a spatula.
Molded tablets produced using formulations2 and 3 (Tables
111.4 and 111.5 respectively) and agedone day, one week, and one
month possess similar dissolution profiles(Figure III.17a).The
slopes of these fitted linesrange from 7.33% per hour to 8.20%per
hour (Figure III.17b) andare very close to the desired sustained
zero-order release rate of 8.33%per hour over 12 hours.
IN VIVO DRUG RELEASE FROM MOLDED TABLETS
Saliva acetaminophen concentrationsin one adult human
subject following oral administrationof molded tablets
(formulation 1 or 2) containing spray-coatedAPAP pellets are given
in Figure 111.18.Both formulations (1 & 2) producedsustained
release of drug but formulation2 with an additional 500mg
acetaminophen given as 4% Aquacoatpellets was able to maintaina
minimum saliva acetaminophenconcentration of 5 Ag/mL throughout
the dosing interval of 12 hours.Absorption was delayed since the
apparent elimination rate constant increasedto 3.68 hr and 4.89 hr
following administration of moldedtablets (formulation 1 and 2)
respectively (Table 111.8).This is consistent with dissolution
results which indicated sustainedrelease of drug (d50m of about 5120
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Figure III.16aDissolution profile of molded tablet andunmolded
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Figure III.16bSimple linear regression of dissolutiondata of
molded tablet and unmolded pelletsusing
formulation 3.0
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Figure III.17aDissolution profile of molded tabletsaged one day,
one week, and one month produced using formulation
3.123
120
100
o80
w
cn<
60
Lu
ct
<
C1--40
a_<
20
0
0 Imm+2.5% AQ+4% AQ-1dayold
Slope=7.33%/hr; R2=0.97
A Imm+3% AQ+4% AQ-1week old
Slope=8.20%/hr; R2=0.96
0
,---
Slope=7.71%/hr; R2=0.97
0 Imm+3% AQ+4% AQ-1month old
6
TIME (hr)
12
Figure III.17bSimple linear regression of dissolutiondata of
molded tablets agedone day, one week, and one
month produced using formulation3.100.00
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Figure 111.18Saliva acetaminophen (APAP)concentration-time
profiles (12-24 hour data) forone subject
receiving two different molded tabletformulations
containing an immediate (Imm) anda sustained
release Aquacoat© (AQ) portion.125
Table 111.8Pharmacokinetic parameters following oral
administration of acetaminophen molded tablets
calculated by non-compartmental methods
Parameters Formulation 1 Formulation 2
K (hr-l)a 0.188 0.142
11/2 (hr)b 3.686 4.88
AUC (µg-hr/mL) 102.809` 108.006
MRT (hr)d 4.824 5.485
C.. (gg/mL) 15.275e 14.034
T. (hr)f 0.75 3.0
CLapp (mL /min)9 389.072 370.350
Vdss (L/kg)h 1.809 1.957
a Slope of the terminallog-linear region of saliva acetaminophen
concentration-time curve calculated by leastsquares regression.
bHalf-life = 0.693/K.Note that a flip-flop model existsfor the
sustained release molded tablet,so this becomes an apparentT112
based on the terminal slope andis not the true half-life of
APAP.
Area under the curve adjusted toa 2400 mg dose.
dMean residence time.
e Maximum observedconcentration adjusted to a 2400mg dose.
f Time to maximumobserved concentration.
g Apparent clearance= Dose/AUC.
hVolume of distribution at steadystate = CLapp X MRT.126
hours).The pharmacokinetic parametersdetermined for this subject
following administration of two moldedtablets given once every 12
hours for a total of two doses (eitherformulation 1 or 2) are
quite similar to each other andare also similar to values obtained
for the same subject followingadministration of two molded tablets
given once every 12 hours fora total of three doses (formulation
3) as later discussed in ChapterIV.Minimum saliva acetaminophen
concentration (Cmin) beginning at time0 hour and at the end of each
dosing interval for each of the administeredmolded tablet
formulations (1 and 2) are shown inFigure 111.19.This plot gives
an idea about drug accumulation in the body andthe achievement of
steady state.Higher Cmin (>5 Ag/mL) at the end of eachdosing
interval is obtained following administrationof two molded tablets
produced using formulation 2, and thisis due to an additional 500
mg of acetaminophen given as a 4% Aquacoat sustainedrelease.127
100-0 500 mg APAP (Imm)+1500mg APAP (3% AQ)
400 mg APAP (Imm)+1500mg APAP (3% AQ) 8 +500 mg APAP (4% AQ)
TIME (hi)
Figure 111.19Minimum saliva acetaminophen (APAP)concentration
(Cmin; 0, 12, and 24 hour data)following
administration of two molded tabletsof formulation
1 (2000 mg dose) and formulation2 (2400 mg dose)
containing an immediate (Imm) anda sustained
release Aquacoat® (AQ) portion.128
CONCLUSIONS
The in vitro dissolution profileselected as desirable based
on across study comparisons of reportedpharmacokinetic-
pharmacodynamic relationshipswas obtained by varying the amount of
coating applied using standard fluid-bedcoating technology.The
3% (4.37 ± 0.63 gm)or the 2.5% (3.75 ± 1.38 gm) coating provides
the desired zero-order release ofAPAP over a 12 hour dosing
interval.Computer simulations using populationaverage
pharmacokinetics and pharmacodynamicscombined with in vitro
dissolution data suggest this dosageform can optimize therapy. In
vitro dissolution and preliminaryin vivo data for the molded
tablets produced using eitherformulation 2 (immediate release
portion of 400 mg acetaminophen anda combination sustained release
portion of 1500 mg APAPas 3% Aquacoat and 500 mg APAP 4% Aquacoat)
or formulation 3 (immediate release portionof 400 mg APAP and a
combination sustained releaseportion of 1500 mg APAPas 2.5%
Aquacoat and 500 mg APAPas 4% Aquacoat) appears to bea promising
sustained release dosage form.The molded tablets have notyet
been evaluated in febrile childrenfor either efficacyor plasma
level-dose relationships, but doprovide the basis fora
pharmacodynamic study.
Simulated plasma acetaminophenconcentration-time curveswere
similar to actual bioavailabilitystudy profiles.In vitro
dissolution data were alsovery helpful in predicting successful129
performance of the molded tablet dosageform following in vivo
administration to an adult human volunteer.Computer simulations
combined with in vitro dissolution datahave been used to designa
dosage form and optimized therapy.130
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CHAPTER IV
MULTIPLE DOSE PHARMACOKINETICS AND RELATIVE
BIOAVAILABILITY OF A NOVEL SUSTAINED RELEASE
ACETAMINOPHEN MOLDED TABLET133
ABSTRACT
An experimental easily swallowable oralsustained release
dosage form of acetaminophen (APAP) thatcan be administered to
patients every 12 hours was evaluated in8 healthy, adult
volunteers.The test product was compared toa well-characterized,
commercially available immediate-releaseacetaminophen caplet.
Multiple doses of these two productswere administered to 8 healthy
human subjects in a two-waycross-over design.Saliva samples were
collected over a period of 24 to 48 hoursdepending upon the
administered treatment.The time course of acetaminophen
concentrations in saliva was analyzed usingboth compartmental and
non-compartmental methods.Results indicate that it is possibleto
maintain the desired therapeuticconcentration over a 12 hour
dosing interval using the molded tabletdosage form.134
INTRODUCTION
Formulation of a new sustained action acetaminophen (APAP)
molded tablet proposed to maintain a minimum plasma acetaminophen
concentration (Crnin) of 5 gg/mL for 12 hours in order to produce
maximum analgesic-antipyretic effects for the entire dosing
interval has been reported (1, Chapter III).
APAP is a widely used non-prescription, non-narcotic
analgesic and antipyretic.Concerns about Reye's syndrome
associated with salicylate use have resulted in APAP becomingone
of the safest and most widely used analgesic-antipyreticsin
children (2-6).It is rapidly absorbed from the gastrointestinal
tract with peak plasma concentrations occuring between 0.5 and2
hours post-dosing.However, it is incompletely available to the
systemic circulation after oral administration anda variable
proportion, depending upon the amount administered, is lostthrough
first-pass metabolism (7-10).APAP is extensively metabolized
(primarily in the liver) and eliminated in the urineas glucuronide
and sulfate conjugates with only 2 to 5% ofa therapeutic dose
being excreted unchanged (11).Mean terminal elimination phase
half-life values for APAP are in the range of 2-3 hours (12,13).
Sustained release formulations tend to reduce peaks and
troughs compared to the more frequent administration ofstandard
formulations (14-16).Such a formulation of APAP could provide
convenience to patients receiving long-term therapy, andmay also135
suppress pain and fever during a whole night followinga single
dose at bed time.Suppositories of APAP produce much flatter
plasma concentration curves comparedto tablets, and thus mimic the
expected plasma concentrations afteran oral sustained release
formulation (17).A marked prolonged antipyretic effectis evident
after administration of suppositories ofAPAP (18,19), and the
antipyretic effect does not dependon a high initial plasma
concentration peak.Pharmacodynamic-pharmacokinetic considerations
across studies have shown that prolonged maximumantipyretic and
analgesic effects are expected solongas the plasma concentration
of APAP is maintained above 5 gg/mL(1).Thus, controlling and
prolonging release of therapeuticconcentrations of APAP should
extend antipyresis and analgesia, therebydecreasing the required
frequency of administration.
A significant limitation in oral controlledrelease dosage
form design is the size of the doseto be administered in order to
elicit therapeutic response.This is especially important fora
relatively large dose drug like acetaminophen(1000 mg every 6
hours), when the half-life is short(2-3 hours).Currently, a
long-acting dosage form of APAP is notavailable commercially.An
easily swallowable, sustained releaseoral dosage form of APAP is
desirable.Polymer film coating technology hasbeen used to
produce controlled release (sustainedaction) acetaminophen beads
that can be molded intoa rapidly disintegrating, easily
swallowable dosage form (1, Chapter III).136
The purpose of this study was to evaluate the
bioavailability of a new, oral controlled releaseacetaminophen
molded tablet relative to a commercially availableproduct (Extra-
Strength Tylenol@ caplet).Relative bioavailability is important
in evaluating dosage forms as lower bioavailabilitymeans that a
patient may not absorb an effective amount of the dose.The molded
tablet contains polymer coated APAP loaded beads whichis designed
to prolong or delay absorption in order to sustaintherapeutic
effect.However, polymer coatings often interfere significantly
with absorption resulting in poor bioavailability.This study is
needed to show that the sustained release moldedtablet does allow
appropriate absorption of the active ingredient.137
MATERIALS AND METHODS
1. BIOAVAILABILTY STUDY DESIGN
Eight healthy volunteers (6 male and 2 female)participated
in this study after written informed consentwas obtained from each
of the volunteers prior to the study.Average age and weight were
28.75 years and 66.49 kg respectively (Table IV.1).The study was
approved by the Oregon State University Protection ofHuman
Subjects Committee.No participants were taking medications
(including oral contraceptives) or alcohol for at least3 days
prior to and throughout the study period, andnone had a history of
chronic disease.Subjects who smoke regularly, were allergic to
acetaminophen, or who received therapy withan enzyme-inducing
agent within the previous 30 dayswere excluded from participation.
One treatment consisted of two molded tabletscontaining
uncoated immediate release beads and coated sustainedrelease
acetaminophen beads, given onceevery 12 hours for a total of three
doses.Each molded tablet containeda combination of sustained
release and immediate release acetaminophen (TableIV.2).
Production of sustained release molded tabletsis detailed in
Chapter III.Tablets were allowed to disintegrate in the mouthand
released beads were swallowed intact.Subjects were advised not to
chew or crush tablet ingredients.The control treatment consisted
of two 500 mg Extra-Strength Tylenol@ Caplets,Control No. FCA969
(McNeil Consumer Products Co., Fort Washington,PA) as immediate138
Table IV.1Vital statistics of subjects
Subject No. Sex Age (yrs) Weight (kg) Height (inches)
1 F 30 53.6 64.0
2 F 24 54.0 67.0
3 M 30 59.1 66.9
4 M 31 62.3 69.0
5 M 30 95.5 72.0
6 M 27 86.0 69.5
7 M 29 70.5 70.0
8 M 29 51.0 65.0
Mean 28.8 66.5 67.9
SD 2.1 15.3 2.5
Range 27-31 51-95.5 64-72139
Table IV.2Composition of molded tablet for acetaminophen pellets
Ingredient Weight (mg)
Uncoated immediate release beads (200mg APAP) 268.0
2.5% Aquacoat coated beads (750mg APAP) 966.0
4% Aquacoat coated beads (250mg APAP) 380.0
Mannitola 736.0
Ac -di -solo 150.0
Total weight 2500.0
a Mannitol powder, J.T. Baker ChemicalCo., Phillipsburg, NJ 08865.
b
Modified cellulose gum, FMC Corp., Philadelphia,PA 19103.140
release product, given onceevery 6 hours for a total of three
doses.
The two treatments were administered randomlyas a two-way
cross-over design on two occasions with a minimum ofa 4 day
washout period between treatments (13).Acetaminophen absorption
depends on the rate of gastric emptying (20) andis delayed with a
full stomach (21).Increasing amounts of carbohydrate in the gut
appear to delay acetaminophen absorption (22,23).Therefore,
subjects were fasted 12 hours prior to and 2 hoursafter the first
dose beginning each treatment phase.They were also required to
observe fasting 2 hours prior and 2 hours afterthe second and
third dose.During the fasting period no foodor beverage other
than water was allowed.
Treatments were administered by volunteers eitherat home or
in the Pharmaceutics laboratory with 6oz. of water.Immediately
after swallowing the dosage form and water, mouthwas rinsed with 3
oz. of Scope® mouthwash (Proctor and Gamble, Cincinnati, OH)
followed by a water rinse to decrease residualdrug concentration
in the oral cavity which may give higherthan expected
concentrations for the first postdose sample.
2. SALIVA SAMPLE COLLECTION
Drug excretion in saliva has been reportedin man (24,25) and
saliva concentrations of acetaminophen havebeen reported to be
proportional to plasma concentrations (13,26-28).Hence,141
collection and measurement of acetaminophenin saliva was preferred
because it presents an accurate and non-invasivemethod of
obtaining information about acetaminophen plasmaconcentrations.
It also allowed the participants to collecttheir own samples
without the discomfort, possible hazards, andnecessary attendance
of medical staff required, for repeatedvenipunctures.
Saliva samples were collected by each subjectin 12 mL glass
centrifuge tubes over a one minute period bychewing on Parafilm
(American Can Co., Greenwich, CT)squares (2.5 cm X 2.5 cm) to
induce saliva production.Subjects were also required to refrain
from drinking beverages, juice, wateror brushing teeth to prevent
artificial dilution of acetaminophen in thesaliva sample, and not
to ingest food immediately preceding salivacollection to avoid
excessive accumulation of particulate matterin samples.Samples
were collected according to the following schedule: 0 hour(just
prior to first dose, second dose, and thirddose with each
treatment), and then 10, 20, 30, 45 minutes,1,1.5, 2, 2.5, 3, 4,
6, 8, and 12 hours after the third dose forthe commercial Tylenol®
caplet treatment and additional samplesat 16, and 24 hours after
the third dose for the molded tablet.Sample tubes were covered
with Parafilm and refrigerated immediatelyafter collection.
All saliva samples were returned to thelaboratory at the end
of each treatment.Samples were frozen at -20°C, thawed, and
centrifuged (Beckman Model TJ-6 Centrifuge, PaloAlto, CA) at 3000
rpm for 30 minutes to remove mucous and particulatematter.142
Salivary supernatant was removed and transferred toa 2.5 mL
polypropylene Cryo-Stor screw-cap vial (Perfector Scientific, Inc.,
Atascadero, CA) and stored at -20°C until analyzed.These were
again centrifuged prior to HPLC analysis.
3. STANDARD ACETAMINOPHEN SOLUTIONS
Stock solutions containing 20, 50, 100, 200, 300, 400, 500,
600, 800, 1000, 1200, and 1500 gg/mL of acetaminophen (Sigma
Chemical Co., St. Louis, MO) were prepared in distilled, deionized
water.An 80 µg /mL solution of 2-acetamidophenol (Sigma Chemical
Co., St. Louis, MO) in distilled water was used as the internal
standard.Standards were prepared by spiking 500 gL of blank
saliva with 25 AL of the above stock solutions.100 AL of standard
or unknown was mixed with 100 AL of internal standard solution in a
250 gL polyethylene centrifuge tube and vortexed for 20 seconds,
prior to injection into a high pressure liquid chromatograph
(HPLC).
4. ACETAMINOPHEN HPLC ASSAY
Acetaminophen concentration in saliva was determined byan
HPLC system consisting of a delivery pump (M-6000A, Waters
Associates, Milford, MA), an automatic sample injector (WISP 712B,
Waters Associates, Milford, MA), a C-1308 guard column with
Perisorb® RP-18 packing material (Upchurch Scientific, Inc., Oak
Harbor, WA), a 4.6 mm X 25 cm reverse phase Zorbax Pro-10 C8143
analytical column (Part No. 884988-902, Du Pont Company,
Wilmington, DE), a fixed wavelength UV detector (Model 440, Waters
Associates, Milford, MA) set at 254 nm, and an integrator (C-R3A
Chromatopac, Shimadzu Corp., Kyoto, Japan).
Saliva acetaminophen concentrations were determined using a
modification of an HPLC procedure used by Borin (29).Mobile phase
consisted of 10% (v/v) methanol in distilled water at a flow rate
of 2.5 mL/min.Injections of 10 gL were made with the UV
absorbance detector set at 0.005 AUFS sensitivity.Integrator
attenuation and chart speed were 5 and 6 mm /min.Retention times
were 2.6 minutes for acetaminophen and 3.4 minutes for 2-
acetamidophenol (Figure IV.1).
Standard curves were generated using the peak area ratios of
acetaminophen:internal standard versus known acetaminophen
concentration fit to a line via linear regression.A typical
standard curve is shown in Figure IV.2.Standard curves were
prepared daily and had coefficients of determination, R2 > 0.994.
The coefficient of variation varied from 4.7 to 8.32% over the
range of 0.95 to 47.62 gg/mL of acetaminophen.The sensitivity of
the assay was approximately 1ag /mL.
5. COMPARTMENTAL ANALYSIS
Saliva acetaminophen concentration data for each subject
following administration of Extra-Strength Tylenol® were analyzed
by PCNONLIN, an iterative nonlinear least squares program using the144
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Figure IV.1Typical chromatogram for acetaminophenand 2-
acetamidophenol.2.0
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Figure IV.2Plot of peak area ratios of acetaminophen
(APAP):internal standard (I.S.)versus known
acetaminophen concentration.
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Nelder-Mead algorithm (30).The time course of acetaminophen
concentrations in saliva were fitted toa linear sum of 2 or 3
exponential terms in the form ofa one or two compartment open
pharmacokinetic model with first order absorptionand a lag time.
The model providing the best fitwas selected based on correlation
coefficient (R > 0.93) of observed and predictedconcentrations,
and lowest condition number, which indicateshow well the program
converged to final estimates.Coefficients and exponents from
fitted functions were used to calculateabsorption rate constant,
lag time, volume of distribution,microconstants, and elimination
half-life.Area under the concentration-timecurve (AUC12_18) was
calculated for the third dose (assumingsteady state) using the
linear trapezoidal rule.Mean residence time (MRT), which involves
a composite of drug release, absorption, and dispositionprocesses
was calculated for a one compartment model with first-orderinput
(31,32) from the relationship MRT= 1 /Ka + 1 /Key.
6. NONCOMPARTMENTAL ANALYSIS
Bioavailability parameters were also calculatedfrom saliva
acetaminophen concentration-timecurves for the last (third) dose
with model-independent calculationsfor both Extra-Strength
Tylenol® and the sustained action moldedtablet.Terminal
elimination rate constants (K)were estimated by least squares
regression of concentration-time datapoints lying in the terminal
log-linear region of thecurves.AUC, AUMC and MRT (AUMC../AUC..)147
were calculated using RSTRIP (33) for the third dose, assuming
steady state has been reached for both treatments.The peak saliva
concentration (C,m) and time to peak concentration (Twx) were
obtained from individual concentration-time profiles for each of
the administered products.Relative bioavailability (Frei) for the
molded tablet was calculated as the ratio of AUC24.36 for the third
dose of the molded tablet divided by AUC12.18 for Extra-Strength
Tylenol® third dose for each subject.AUC12.18 adjusted to a 2400
mg dose were made for the third dose of Extra-Strength Tylenol®
prior to calculation of Fret.Clearance apparent (Clapp) was
calculated as dose/AUC and apparent volume of distribution at
steady state (Vdss) was calculated as (Clapp X MRT) (34).Average
concentration-time data for both treatments were also used to
calculate average non-compartmental pharmacokinetic parameters in
the same manner as individual concentration-time profiles.
7. STATISTICAL ANALYSIS OF DATA
Statistical analysis of selected bioavailability parameters
and dose-corrected parameters was performed using analysis of
variance (ANOVA).Calculations were performed using STATGRAPHICS
software (35).Statistical significance among treatments,
period/days, and subjects was evaluated using a three-way ANOVA.148
RESULTS AND DISCUSSION
1. COMPARTMENTAL FITTING OF EXTRA-STRENGTH TYLENOL® DATA
Pharmacokinetics of acetaminophen after oral and intravenous
administration are reported to be best described by one and two
compartment open models (9,10,13,17,29,36).Saliva acetaminophen
concentration-time curves for all subjects were well computer-
fitted by a one compartment open model with first order absorption
and first order elimination, and a lag time.Individual
concentration-time data and curves for each subject are given in
appendices A and B.Subject 4 received the treatment twice and the
mean concentration-time data are reported in Table IV.3.The
average concentration-time data for this subject are reported in
Appendix A, and the concentration-time profile with standard
deviation error bars are shown in Appendix B.Pharmacokinetic
parameters at steady state for a one compartment open model
following administration of 1000 mg acetaminophen from Extra-
Strength Tylenol® caplets are presented in Table IV.3 (third dose).
Average maximum saliva acetaminophen concentration (Cmm) and
average time to maximum concentration (TAX) at steady state were
19.64 gg/mL and 1.11 hour respectively, indicating rapid absorption
and distribution (Table IV.3).The mean absorption rate constant
(Ka) was 6.57 hour-1 also indicating rapid absorption.Area under
the curve (AUC, measure of extent of absorption)was calculated for
the third dose (assuming steady state) using linear trapezoidalTable IV.3Pharmacokinetic parametersa (steady state 12-18 hour) for one compartment open model
following multiple oral administration of 2 X 500 mg Extra-Strength Tylenol® caplets
Subject
No.
K8
(hr-1)
Ket
(hr-1)
T
1/2
(hr)
Ttag
(hr)
AUC
(µg-hr/mL)
Cmax
(jtg /mL)
Tmax
(hr)
MRT
(hr)
1 9.999 0.381 1.820 0.132 94.269 33.588 0.472 2.726
2 8.774 0.414 1.675 0.285 90.154 33.374 0.651 2.531
3 9.999 0.309 2.241 0.274 60.794 19.807 0.633 3.333
4 2.930 0.391 1.773 0.598 37.459 12.110 1.391 2.899
5 9.847 0.341 2.030 0.886 41.425 14.048 1.240 3.030
6 2.110 0.438 1.583 0.421 37.682 12.060 1.361 2.758
7 2.678 0.279 2.486 0.648 35.089 9.801 1.591 3.960
8 6.223 0.261 2.655 0.969 73.948 22.328 1.501 3.991
Mean 6.570 0.352 1.969d 0.527 58.852 19.639 1.105 3.154
S.D.b 3.308 0.060 0.367 0.281 23.022 8.893 0.417 0.523
C.V.(%)c50.343 17.137 18.056 53.433 39.118 45.280 37.711 16.590
a Parameters estimated using PCNONLIN.Nelder-Mead algorithm.
bStandard deviation.
C Coefficient of variation.
dHalf-life = 0.693/Ke.150
rule.Mean AUC from one compartment model fitted data for Extra-
Strength Tylenol* was 58.85 Ag/mL (Table IV.3).The mean
elimination rate constant (Ket) was 0.35 hour' and the mean
elimination half-life (T112) was 2.03 hour.For all concentration-
time curves there was a lag time (Tin) between administration of
the drug and onset of absorption.Mean lag time was found to be
0.53 hour.Mean residence time (MRT) was calculated for a one
compartment open model following oral administration as (1/K, +
1/Ket).The average MRT value was 3.15 hour.All these calculated
pharmacokinetic parameters are highly consistent with those found
by other investigators (9,10,12,29,37, 38,39) indicating similar
absorption, distribution, and elimination processes in the subjects
participating in this study.
The mean saliva acetaminophen concentrations for all subjects
and for each acetaminophen product are shown in Figure IV.3.
Variability at each time point is shown in Figures IV.4 and IV.5
for Extra-Strength Tylenol® and molded tablet, respectively.
Minimum saliva acetaminophen concentrations (Cmin) beginning at time
0 hour and at the end of each dosing interval for each of the
administered product were also averaged at each time point and are
shown in Figure IV.6 with standard deviation error bars showing
variability in the data.This plot confirms drug accumulation in
the body and the achievement of a steady state (i.e. dose
administered is equal to that which has been eliminated).The
observed Cmin for Extra-Strength Tylenol® is consistent with100.00
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Figure IV.3Mean saliva acetaminophen concentration-time profiles
for all subjects.Extra-Strength Tylenol® caplet
(1000 mg dose, 12-18 hour data) and molded tablet
(2400 mg dose, 24-36 hour data).100.00
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Figure IV.4Variability of average concentration time profiles
(12-18 hour) for subjects receiving Extra-Strength
Tylenol® caplets (1000 mg dose).Standard deviation
error bars are shown except in those cases when they
are smaller than the symbol.0
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Figure IV.5Variability of average concentration time profiles
(24-36 hour) for subjects receiving molded tablet
(2400 mg dose).Standard deviation error bars are
shown except in those cases when theyare smaller than
the symbol.15
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Figure IV.6Variability of average minimum saliva acetaminophen
concentration (qmn) for Extra-Strength Tylenol® caplet
(1000 mg dose; 0, 6,12, and 18 hour data) and molded
tablet (2400 mg dose; 0, 12, 24, and 36 hour data).
Standard deviation error bars are shown.155
knowledge that a dosage interval which equals or exceeds three
times the biological half-life of the drug will result in
negligible drug accumulation relative to a single dose (40).
However, saliva acetaminophen concentrations of 5 Ag/mLor greater
were maintained throughout each dosing interval by the sustained
action molded tablet.Computer simulation using a dual input
function following multiple oral admistration of the molded tablet
did predict maintenance of a minimum concentration of 5 Ag/mL (1,
Chapter III).The average dose-corrected saliva acetaminophen
concentration following administration of Extra-Strength Tylenol®
caplets decreased to subtherapeutic levels (<5 Ag/mL) at the end of
12 hours.
One compartment open model pharmacokinetic parameters were
calculated for the average concentration-time data for Extra-
Strength Tylenol® caplet and are given in Table IV.4.All
pharmacokinetic parameters except the absorption rate constant (Ka)
and the lag time (TLag) determined from the average concentration-
time profile at steady state are similar to the average values
calculated from individual saliva acetaminophen concentration-time
curves.While the average Ka value was still within therange
observed for individual subjects, the lag time was shorter.
Mean concentration-time profile following administration of
two 1200 mg molded tablets given once every 12 hours for a total of
three doses is shown in Fig. IV.5.The saliva acetaminophen
concentration-time curve is consistent with that of a wellTable IV.4One compartment open model pharmacokinetic parameters' determined from average
concentration-time profile (12-18 hour) for Extra-Strength Tylenol@ caplet
(1000 mg dose)
K. K.( T1,
'2 Ttag AUC C. T. MRT
(hr-1) (hr.') (hr) (hr) (µg-hr/mL) (pg/mL) (hr) (hr)
2.066 0.305 2.269 0.066 59.286 16.012 1.152 3.758
a Parameters estimated using PCNONLIN.Nelder-Mead algorithm.157
formulated sustained release dosage form (i.e. rapid acheivement of
therapeutic concentration and maintenance of that concentration
over the dosing period of 12 hours).Saliva acetaminophen
concentrations of 5 Ag/mL or greater which correlate with
therapeutic efficacy were acheived quickly and maintained for the
entire dosing interval of 12 hours.Average maximum saliva
acetaminophen concentration of 21.76 Ag/mL was acheived at 2.13
hours.Decline of saliva acetaminophen concentration was slower
than for the immediate release product (Extra-Strength Tylenol®
caplet), as would be expected from a sustained release dosage from.
Also, it appears that there is minimum lag time, if any, from the
molded tablet compared to the Extra-Strength Tylenol® caplets
(Figure IV.3).This may be due to the fact that the molded tablet
contains multiple units of coated and uncoated acetaminophen beads
which provides a larger surface area for drug dissolution and
absorption compared to the single unit Extra-Strength Tylenol®
caplets.Hence, rapid absorption and drug distribution can occur
following administration of the molded tablet.
2. NONCOMPARTMENTAL FITTING OF ACETAMINOPHEN DATA
Noncompartmental bioavailability parameters were also
calculated from saliva acetaminophen concentration-time data for
each of the administered products and are presented in Tables IV.5
and IV.6.Area under the curve (AUC) and area under the moment
curve (AUMC) were calculated for the third dose (assuming steadyTable IV.5Non-compartmental pharmacokinetic parameters for acetaminophen following multiple oral
administration of 2 X 500 mg Extra-Strength Tylenol® Caplets (1000mg dose)
Parameters Subject Number Mean S.D.a C.V.(X)b
1 2 3 4 5 6 7 8
K (hr
-1 c
0.344 0.246 0.328 0.334 0.189 0.398 0.249 0.271 0.295 0.063 21.385
T
1/2
(hr)d
2.015 2.817 2.114 2.077 3.663 1.742 2.780 2.559 2.349 0.557 23.363
AUC (µg-hr/m0a 92.268 86.116 60.339 39.248 41.435 39.154 36.254 75.981 58.849 21.627 36.750
AUMC (Ag-hr PEL) 188.312 184.934 127.497 106.080 111.762 100.706 106.543 235.171 145.126 47.392 32.656
MRT (hr)g 2.041 2.148 2.113 2.703 2.697 2.572 2.939 3.095 2.538 0.372 14.640
Cmax (Ag/mL)
h 35.392 36.301 22.546 11.781 15.291 11.878 11.110 22.409 20.838 9.644 46.279
Tex (hr) 0.5 0.5 0.75 2.0 1.5 1.5 1.5 1.5 1.219 0.522 42.829
CL
a (mL/min)j 180.634 193.538 276.217 424.651 402.234 425.668 459.722 219.353 322.752 109.433 33.906
Vd
ss(L/kg)
k
0.412 0.462 0.593 1.106 0.682 0.764 1.151 0.799 0.746 0.254 34.048
AUC (Ag/mL) 221.443 206.678 144.814 94.195 99.445 93.970 87.009 182.354 141.238 51.905 36.750
C
MaX(Ag/mL)m 84.941 87.122 54.111 28.273 36.697 28.507 26.665 53.781 50.012 23.145 46.279
a
b
d
e
f
g
h
k
m
Standard deviation.
Coefficient of variation.
Slope of the terminal log-linear region of saliva acetaminophen concentration-time curve calculated by leastsquares regression.
Half-life = 0.693/K.
AUC for the third dose (12-18 hour).
AUMC for the third dose (12-18 hour).
MRT = AUMC/AUC.
Maximum observed concentration.
Time to maximum observed concentration.
Apparent clearance = Dose/AUC = Vdss/MRT.
Volume of distribution at steady state = CL
a X MRT.
Area under the curve adjusted to a 2400 mg dose.
Maximum observed concentration adjusted to a 2400 mg dose.Table IV.6Non-compartmental pharmacokinetic parameters for acetaminophen following multiple oral
administration of 2 X 1200 mg Molded Tablets (2400 mg dose)
Parameters Subject Number Mean S.D.a C.V.(%)b
1 2 3 4 5 6 7 8
K (hr
-1
)c 0.118 0.135 0.162 0.119 0.113 0.309 0.143 0.136 0.154 0.060 39.178
T1/2(hr)d
5.882 5.139 4.289 5.848 6.149 2.241 4.842 5.081 4.5 1.170 23.715
AUC (µg-hr/ml.)6 195.333 174.843 114.646 107.811 97.495 56.901 120.240 275.423 142.836 64.549 45.191
AUMC (µg-hr2/mL)
f 947.290 818.411 570.910 559.320 533.791 289.982 470.6671278.895 683.658294.310 43.049
MRT (hr)g 4.850 4.681 4.980 5.188 5.475 5.096 3.914 4.643 4.853 0.437 9.008
Cmax(gg/mL)
h
35.543 25.536 14.973 14.009 11.777 7.923 26.382 42.919 21.758 10.941 50.288
Tmax (hr)i 3.0 2.0 4.0 3.0 2.5 1.5 0.5 0.5 2.125 1.166 54.867
CL
a (mL/min)i 204.778 228.776 348.902 371.019 410.280 702.977 332.668 145.231 343.079 160.585 46.807
Vd(L/kg)k
ss 1.111 1.190 1.764 1.855 1.412 2.50 1.109 0.793 1.467 0.512 34.877
t
Fret 0.882 0.846 0.792 1.145 0.980 0.606 1.382 1.510 1.018 0.288 28.257
a Standard deviation.
bCoefficient of variation.
Slope of the terminal log-linear region of saliva acetaminophen concentration-time curve calculated by least squares regression.
d
Half-life = 0.693/K.
AUC for the third dose (24-36 hour).
AUMC for the third dose (24-36 hour).
g MRT = AUMC/AUC.
h Maximum observed concentration.
Time to maximum observed concentration.
Apparent clearance = Dose/AUC = Vd
ss
/MRT.
k Volume of distribution at steadystate = CLa MRT. pp
Relative bioayailability = AUC (24-36 hour) molded tablet/AUC (12-18 hour) for Extra-Strength Tylenol caplets
adjusted to a 2400 mg dose.
cn
.0160
state) for each treatment.Ratio of AUMC to AUC gave mean
residence time (MRT).MRT has been defined as the mean time for
intact drug molecules to transit through the body (31).
The pharmacokinetic parameters calculated for the Extra-
Strength Tylenol® caplets by the one compartment open model and the
model-independent method are in good agreement (Tables IV.3, IV.4,
and IV.5).The steady state volume of distribution (Vdss)
calculated by non-compartmental methods (Table IV.5) range from
0.41 L/kg to 1.15 L/kg with an average value of 0.75 L/kg.Volume
of central compartment (V1) for 1000 mg injections and 1000 mg
given orally have been reported to be 0.42-0.94 L/kg (7,8,16), and
0.86 L/kg (41) respectively.
Selected average bioavailability parameters following
administration of each acetaminophen product are given in Table
IV.7.Three-way analysis of variance (ANOVA) for statistical
significance among treatments, periods/days, and subjects were
performed using STATGRAPHICS.Period effects were not found to be
significant at p < 0.05.Statistically significant differences (p
< 0.01) between treatments were observed for terminal slopes (K),
half-life (T112), and mean residence time (MRT) at steady state
(Table IV.7).Thus, the apparent, but not true, half-life of
acetaminophen in saliva is prolonged as would be expected fora
sustained release product (slow drug input).Because elimination
is slower for the molded tablet, transit of drug molecules will be
slower.This is reflected in the magnitude of MRT for the molded161
Table IV.7Summary statistics for average pharmacokinetic
parametersa following oral administration of
acetaminophen products calculated by non-compartmental
methods
Parameters Extra-Strength
Tylenol® Caplets
Molded Tablets ANOVAb
K (hr-l)` 0.295±0.063 0.154± 0.060 <0.01
T112(hr)d 2.349±0.557 4.5 ± 1.170 <0.01
AUC (jig- hr /mL) 141.238±51.905e 142.836±64.549 N.S.
MRT (hr)f 2.538± 0.372 4.853±0.437 <0.01
C. (gg/mL) 50.012±23.145' 21.758±10.941 0.01
T. (hr)h 1.219±0.522 2.125± 1.166 N.S.
CLapp (mL /min)' 322.752± 109.433 343.079± 160.585 N.S.
Vdas (L/kg)j 0.746±0.254 1.467± 0.512 0.02
Frei k 1.0 ± 0.0 1.018±0.288 N.S.
a Average values ± standard deviation.
b Analysis of variance, significance level ofdifference among
treatments; N.S. (not significant at p < 0.05).
Slope of the terminal log-linear region of saliva acetaminophen
concentration-time curve calculated by least squares regression.
d Half-life= 0.693/K.Note that a flip flop model exists for the
sustained release molded APAP tablet, so this becomes an apparent
T1/2 based on the terminal slope and is not the true half-life of
APAP.
eArea under the curve adjusted to a 2400 mg dose.
f Mean residence time.
g Maximum observed concentration adjusted toa 2400 mg dose.
h Time to maximum observed concentration.
i
Apparent clearance = Dose/AUC = Vdas/MRT.
j Volume of distribution at steady state= CLapp X MRT.
k Relative bioavailability= AUC (24-36 hour) molded tablet/AUC
(12-18 hour) for Extra-Strength Tylenol® caplets.162
tablet and is consistent with sustained release of acetaminophen.
Maximum observed saliva acetaminophen concentration (C..) corrected
for dose was found to be statistically significant (p= 0.01).
Such differences would be expected between an immediate release
dosage form (Extra-Strength Tylenol ®) and a sustained release
dosage form (molded tablet).Time to maximum observed saliva
acetaminophen concentration (T.), dose normalized area under the
curve (AUC), apparent clearance (CLapp), and relative
bioavailability (Fret) were not statistically significant (p < 0.05)
between treatments.Both products appear to possess equal rate and
extent of absorption.
Although statistically not significant, mean T.. was longer
for the molded tablet.This may be due to the combination of three
different acetaminophen release rates (Table IV.2) resulting from
the immediate release portion, 2.5% Aquacoat sustained action
portion, and the 4% Aquacoat portion in the molded tablet dosage
form (Chapter III).Average apparent clearance values of 322.75
mL/min and 343.08 mL/min following oral administration of Extra-
Strength Tylenol* caplets and sustained release molded tablet
respectively, are consistent with values ranging from 291.4 mL/min
to 400 mL/min reported by other investigators (8,9,10,17,38).
Significant differencesin apparent K (p = 0.04), dose corrected
AUC (p = 0.02), and CLE44, (p = 0.05) were observed among subjects,
which would be expected due to intersubject biological variation.
Steady state apparent volume of distribution (Vdss) presented in163
Table IV.7 are found to be statistically significant (p = 0.02)
between treatments.However, Vdss values for both treatments are
within the range reported in the literature (8,9,17,38,41).
Statistical test for carryover, or sequence effects were
performed for all the bioavailability parameters listed in Table
IV.7.Sequence effects were not found to be significant at the 5%
level.
Pharmacokinetic parameters determined from average saliva
acetaminophen concentration-time profiles by non-compartmental
methods are presented in Table IV.8.The parameter values are
comparable to values listed in Table IV.7 and are also consistent
to values reported in the literature.164
Table IV.8Non-compartmental pharmacokinetic parameters for
acetaminophen products determined from average saliva
acetaminophen concentration-time profile
Mean Parameters Extra-Strength
Tylenol® Caplets
Molded Tablets
K (hr-1)a 0.263 0.154
T1f2 (hr)b 2.635 4.5
AUC (µg-hr/mL) 141.552' 146.101
AUMC (jig- hr2 /mL) 349.162d 719.499
MRT (hr)e 2.459 4.925
C. (gg/mL) 41.595f 18.618
T. (hr)9 1.5 0.75
CLapp (mL/min)h 282.582 273.784
Vdss( L/kg )1 0.627 1.217
Fret' 1.0 1.032
a
Slope of the terminal log-linear region of saliva acetaminophen
concentration-time curve calculated by least squares regression.
bHalf-life = 0.693/K.Note that a flip flop model exists for the
sustained release molded APAP tablet, so this becomesan apparent
T112 based on the terminal slope and is not the true half-life of
APAP.
' Area under the curve adjusted toa 2400 mg dose.
d
Area under the moment curve adjusted to a 2400 mg dose.
e Mean residence time.
Maximum observed concentration adjusted to a 2400mg dose.
g Time to maximum observed concentration.
h
Apparent clearance = Dose/AUC = VdSS /MRT.
1Volume of distribution at steady state= CLapp X MRT.
'Relative bioavailability = AUC (24-36 hour) molded tablet/AUC
(12-18 hour) for Extra-Strength Tylenol® caplets.165
CONCLUSIONS
Bioavailability for the sustained release molded tablet is
comparable to that of the immediate release product.Hence, the
extent of bioavailability from the molded tablet has not been
affected by presystemic biotransformation due to either first-pass
hepatic extraction or metabolism in the epithelium, and or lumen of
the gastrointestinal tract, or by a combination of theseprocesses
as are reported to occur at single doses below 625 mg (9,10,29).
Amount of drug absorbed at steady state from lower doses (325 mg)
was reported to be not different from that absorbed from higher
doses (650-1000 mg) following multiple oral administration of
immediate release Tylenol® tablets (38).
Simulated saliva acetaminophen concentration-time curveswere
similar to those obtained in this bioavailability study.In vitro
dissolution data were very helpful in predicting successful
performance of the molded tablet following in vivo administration.
Computer simulations combined with in vitro dissolution data has
proven to be a good approach to dosage form design, which should
optimize therapy.
Pharmacokinetic parameters following administration of Extra-
Strength Tylenol® caplets and selected parameters following
administration of sustained action molded tablet were consistent
with those reported in the literature.
Polymer coated acetaminophen beads were effective in166
maintaining saliva acetaminophen concentrations of 5 Ag/mLover a
12 hour dosing interval.Prolonged release of therapeutic
acetaminophen concentrations would likely extend antipyresis and
analgesia, thereby reducing the required frequency of
administration.This type of dosage form should be of benefit to
any age patient who can swallow the disintegrated tablet without
chewing the released beads.167
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APPENDIX A
SALIVA ACETAMINOPHEN CONCENTRATION-TIME CURVES
FOR INDIVIDUAL SUBJECTS1100.00
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Figure A.1Observed saliva acetaminophen concentration-time
profiles for subject 1.Extra-Strength Tylenol® caplet
(1000 mg dose, 12-18 hour data) and molded tablet (2400
mg dose, 24-36 hour data).100.00
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Figure A.2Observed saliva acetaminophen concentration-time
profiles for subject 2.Extra-Strength Tylenol® caplet
(1000 mg dose, 12-18 hour data) and molded tablet (2400
mg dose, 24-36 hour data).100.00
10.00
1.00
0.10
0.01
O
00 Tylenol
Molded Tablet
185
0 10 15
TIME (hr)
20 25
Figure A.3Observed saliva acetaminophen concentration-time
profiles for subject 3.Extra-Strength Tylenol@ caplet
(1000 mg dose, 12-18 hour data) and molded tablet (2400
mg dose, 24-36 hour data).100.00
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Figure A.4Observed saliva acetaminophen concentration-time
profiles for subject 4.Extra-Strength Tylenol® caplet
(1000 mg dose, 12-18 hour data) and molded tablet (2400
mg dose, 24-36 hour data).1 0 0.00
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Figure A.5Observed saliva acetaminophen concentration-time
profiles for subject 5.Extra-Strength Tylenol® caplet
(1000 mg dose, 12-18 hour data) and molded tablet (2400
mg dose, 24-36 hour data).100.00
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Figure A.6Observed saliva acetaminophen concentration-time
profiles for subject 6.Extra-Strength Tylenol® caplet
(1000 mg dose, 12-18 hour data) and molded tablet (2400
mg dose, 24-36 hour data).100.00
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Figure A.7Observed saliva acetaminophen concentration-time
profiles for subject 7.Extra-Strength Tylenol® caplet
(1000 mg dose, 12-18 hour data) and molded tablet (2400
mg dose, 24-36 hour data).100.00
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Figure A.8Observed saliva acetaminophen concentration-time
profiles for subject 8.Extra-Strength Tylenol® caplet
(1000 mg dose, 12-18 hour data) and molded tablet (2400
mg dose, 24-36 hour data).191
APPENDIX B
MINIMUM SALIVA ACETAMINOPHEN CONCENTRATION (Cmin)
FOR INDIVIDUAL SUBJECTS192
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Figure B.1Minimum saliva acetaminophen concentration (Cron) for
subject 1.Extra-Strength Tylenol® caplet (1000 mg
dose; 0, 6, 12, and 18 hour data) and molded tablet
(2400 mg dose; 0, 12, 24, and 36 hour data).193
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Figure B.2Minimum saliva acetaminophen concentration (Cmin) for
subject 2.Extra-Strength Tylenol® caplet (1000 mg
dose; 0, 6, 12, and 18 hour data) and molded tablet
(2400 mg dose; 0, 12, 24, and 36 hour data).194
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Figure B.3Minimum saliva acetaminophen concentration (Cmin) for
subject 3.Extra-Strength Tylenol@ caplet (1000 mg
dose; 0, 6, 12, and 18 hour data) and molded tablet
(2400 mg dose; 0, 12, 24, and 36 hour data).195
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Figure B.4Minimum saliva acetaminophen concentration (Cmin) for
subject 4.Extra-Strength Tylenol® caplet (1000 mg
dose; 0, 6, 12, and 18 hour data) and molded tablet
(2400 mg dose; 0, 12, 24, and 36 hour data).196
10
0-0 Tylenol
Molded Tablet
8
0
Figure B.5
6 12 18 24 30 36
TIME (hr)
Minimum saliva acetaminophen concentration (cid for
subject 5.Extra-Strength Tylenol® caplet (1000 mg
dose; 0, 6, 12, and 18 hour data) and molded tablet
(2400 mg dose; 0, 12, 24, and 36 hour data).197
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Figure B.6Minimum saliva acetaminophen concentration (Cmin) for
subject 6.Extra-Strength Tylenol® caplet (1000 mg
dose; 0, 6, 12, and 18 hour data) and molded tablet
(2400 mg dose; 0, 12, 24, and 36 hour data).198
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Figure B.7Minimum saliva acetaminophen concentration (Cmin) for
subject 7.Extra-Strength Tylenol® caplet (1000 mg
dose; 0, 6, 12, and 18 hour data) and molded tablet
(2400 mg dose; 0, 12, 24, and 36 hour data).25
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Figure B.8Minimum saliva acetaminophen concentration (Cmin) for
subject 8.Extra-Strength Tylenol® caplet (1000 mg
dose; 0, 6, 12, and 18 hour data) and molded tablet
(2400 mg dose; 0,12, 24, and 36 hour data).200
APPENDIX C
SALIVA ACETAMINOPHEN CONCENTRATION-TIME DATA
FOR INDIVIDUAL SUBJECTSTable C.1Saliva acetaminophen concentrations (gg/mL) following oral administration of two 500 mg
Extra-Strength Tylenol® caplets (1000 mg dose) once every 6 hours for a total of 3 doses
TIME
(hr) 1 2 3
SUBJECT NUMBER
4 5 6 7 8
MEAN SD'
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.265 0.000 0.033 0.088
6.000 3.434 5.533 2.383 3.072 1.271 1.476 2.295 4.598 3.008 1.385
12.000 5.396 5.616 4.654 2.608 2.550 1.184 1.828 4.685 3.565 1.606
12 + 0.167 10.411 4.884 3.529 2.108 3.475 1.506 1.931 4.055 3.987 2.657
12 + 0.33334.629 12.020 10.060 2.357 3.545 1.523 1.606 4.817 8.820 10.421
12 + 0.50035.392 36.301 22.186 2.621 3.721 2.653 1.648 4.417 13.617 14.270
12 + 0.75030.39433.702 22.546 5.558 4.590 8.733 3.209 4.472 14.150 11.856
12 + 1.000 27.018 26.935 17.770 11.156 10.507 10.781 6.686 4.513 14.421 8.091
12 + 1.500 19.815 21.817 19.000 15.291 11.878 11.110 22.409 17.331 4.267
12 + 2.000 15.899 19.172 15.007 11.781 10.775 10.795 8.277 20.465 14.021 4.054
12 + 2.500 16.423 15.742 11.779 9.504 7.853 9.351 7.865 18.442 12.120 3.914
12 + 3.000 15.207 13.149 9.250 7.253 7.037 6.932 8.581 14.153 10.195 3.207
12 + 4.000 11.154 11.170 5.536 4.496 5.184 4.801 4.937 13.755 7.629 3.499
12 + 6.000 7.005 5.792 3.082 2.307 4.167 1.888 3.273 6.442 4.245 1.818
12 + 8.000 3.244 4.087 1.844 1.250 3.269 1.066 1.956 4.507 2.653 1.217
12 + 12.00 0.460 1.767 0.377 1.172 1.290 1.013 0.587
a Standard deviation.Table C.2Saliva acetaminophen concentrations (Ag/mL) following oral administration of two 1200 mg
molded tablets (2400 mg dose) once every 12 hours for a total of 3 doses
TIME
(hr) 1 2 3
SUBJECT NUMBER
4 5 6 7 8
MEAN SD'
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
12.000 6.905 8.097 3.773 3.388 4.629 1.870 3.353 13.440 5.682 3.491
24.000 7.353 11.304 3.724 4.642 5.576 2.183 6.491 21.439 7.964 5.697
24 + 0.167 15.796 13.241 6.632 11.112 7.873 3.406 34.660 13.246 9.555
24 + 0.333 12.339 6.922 9.239 6.110 4.462 37.133 12.701 11.208
24 + 0.500 18.300 15.012 9.554 12.736 10.021 5.46926.38242.919 17.549 11.282
24 + 0.667 16.486 16.486 0.000
24 + 0.750 17.907 13.836 11.876 10.890 19.10338.093 18.618 9.202
24 + 0.833 18.359 8.495 13.427 6.975
24 + 1.000 19.983 19.549 11.666 11.586 9.414 5.787 18.29337.183 16.683 9.115
24 + 1.500 20.599 23.142 14.855 11.214 10.712 7.923 14.75537.043 17.530 8.769
24 + 2.000 24.801 25.536 14.591 11.796 7.729 4.751 18.37337.810 18.173 10.164
24 + 2.500 24.702 23.870 12.917 11.614 11.777 5.891 20.30533.227 18.038 8.430
24 + 3.000 30.543 21.987 14.172 14.009 10.903 6.679 15.689 26.124 17.513 7.515
24 + 4.000 23.702 19.927 14.973 13.209 7.809 6.373 14.57633.122 16.711 8.174
24 + 6.000 17.006 17.754 8.472 7.621 5.849 8.247 23.439 12.627 6.208
24 + 8.000 9.071 7.872 7.909 7.527 7.178 5.224 7.729 14.934 8.431 2.656
24 + 12.00 8.317 6.102 4.218 4.304 6.180 1.146 5.097 7.296 5.332 2.060
24 + 16.00 4.432 4.100 2.548 2.908 1.857 2.432 4.456 3.248 0.985
24 + 24.00 2.270 1.272 0.503 1.375 0.737 2.220 1.047 0.838
aStandard deviation.